EP2490702A1 - Treatment using reprogrammed mature adult cells - Google Patents
Treatment using reprogrammed mature adult cellsInfo
- Publication number
- EP2490702A1 EP2490702A1 EP09736651A EP09736651A EP2490702A1 EP 2490702 A1 EP2490702 A1 EP 2490702A1 EP 09736651 A EP09736651 A EP 09736651A EP 09736651 A EP09736651 A EP 09736651A EP 2490702 A1 EP2490702 A1 EP 2490702A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- committed
- patient
- cell
- reprogrammed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title description 82
- 238000000034 method Methods 0.000 claims abstract description 124
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 208000035475 disorder Diseases 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 645
- 210000000130 stem cell Anatomy 0.000 claims description 80
- 239000003795 chemical substances by application Substances 0.000 claims description 62
- 210000004369 blood Anatomy 0.000 claims description 54
- 239000008280 blood Substances 0.000 claims description 54
- 210000001519 tissue Anatomy 0.000 claims description 52
- 230000008672 reprogramming Effects 0.000 claims description 41
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 39
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 35
- 210000000265 leukocyte Anatomy 0.000 claims description 33
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 30
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 29
- 210000001185 bone marrow Anatomy 0.000 claims description 28
- 230000004069 differentiation Effects 0.000 claims description 28
- 230000003394 haemopoietic effect Effects 0.000 claims description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- 210000002569 neuron Anatomy 0.000 claims description 24
- 210000003743 erythrocyte Anatomy 0.000 claims description 22
- 206010012601 diabetes mellitus Diseases 0.000 claims description 20
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 229960000890 hydrocortisone Drugs 0.000 claims description 18
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 17
- 229960003957 dexamethasone Drugs 0.000 claims description 17
- 239000002609 medium Substances 0.000 claims description 17
- 201000006938 muscular dystrophy Diseases 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 16
- 230000001737 promoting effect Effects 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 210000001772 blood platelet Anatomy 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 210000004698 lymphocyte Anatomy 0.000 claims description 12
- 210000003205 muscle Anatomy 0.000 claims description 12
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 claims description 11
- 208000018737 Parkinson disease Diseases 0.000 claims description 11
- 235000010323 ascorbic acid Nutrition 0.000 claims description 11
- 239000011668 ascorbic acid Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 208000005264 motor neuron disease Diseases 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- 206010019196 Head injury Diseases 0.000 claims description 10
- 208000005980 beta thalassemia Diseases 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 10
- 208000017169 kidney disease Diseases 0.000 claims description 10
- 208000020431 spinal cord injury Diseases 0.000 claims description 10
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 claims description 9
- 241000711549 Hepacivirus C Species 0.000 claims description 9
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 claims description 9
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 9
- 208000019693 Lung disease Diseases 0.000 claims description 9
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 9
- 210000001616 monocyte Anatomy 0.000 claims description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 8
- 239000003104 tissue culture media Substances 0.000 claims description 8
- 229930024421 Adenine Natural products 0.000 claims description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 7
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 229960000643 adenine Drugs 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 206010003883 azoospermia Diseases 0.000 claims description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 7
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 7
- 210000004153 islets of langerhan Anatomy 0.000 claims description 7
- 230000009245 menopause Effects 0.000 claims description 7
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 7
- 230000001537 neural effect Effects 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 6
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 230000002500 effect on skin Effects 0.000 claims description 6
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 6
- 210000003038 endothelium Anatomy 0.000 claims description 6
- 210000003714 granulocyte Anatomy 0.000 claims description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 6
- 210000003593 megakaryocyte Anatomy 0.000 claims description 6
- 229930002330 retinoic acid Natural products 0.000 claims description 6
- 229960001727 tretinoin Drugs 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 201000004569 Blindness Diseases 0.000 claims description 5
- 229930182816 L-glutamine Natural products 0.000 claims description 5
- 208000026072 Motor neurone disease Diseases 0.000 claims description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 5
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 210000001789 adipocyte Anatomy 0.000 claims description 5
- 210000002821 alveolar epithelial cell Anatomy 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 5
- 238000002617 apheresis Methods 0.000 claims description 5
- 210000003651 basophil Anatomy 0.000 claims description 5
- 210000001612 chondrocyte Anatomy 0.000 claims description 5
- 150000001875 compounds Chemical group 0.000 claims description 5
- 210000003979 eosinophil Anatomy 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 210000004602 germ cell Anatomy 0.000 claims description 5
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 208000000509 infertility Diseases 0.000 claims description 5
- 230000036512 infertility Effects 0.000 claims description 5
- 231100000535 infertility Toxicity 0.000 claims description 5
- 210000002752 melanocyte Anatomy 0.000 claims description 5
- 210000000440 neutrophil Anatomy 0.000 claims description 5
- 230000000414 obstructive effect Effects 0.000 claims description 5
- 210000000287 oocyte Anatomy 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011708 vitamin B3 Substances 0.000 claims description 5
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 208000018240 Bone Marrow Failure disease Diseases 0.000 claims description 4
- 206010065553 Bone marrow failure Diseases 0.000 claims description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 239000005700 Putrescine Substances 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 230000001464 adherent effect Effects 0.000 claims description 4
- 231100000360 alopecia Toxicity 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 229960002756 azacitidine Drugs 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 230000002489 hematologic effect Effects 0.000 claims description 4
- 229960000905 indomethacin Drugs 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 210000002510 keratinocyte Anatomy 0.000 claims description 4
- 210000003292 kidney cell Anatomy 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 210000004409 osteocyte Anatomy 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 208000037816 tissue injury Diseases 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 claims description 3
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 3
- UIAYVIIHMORPSJ-UHFFFAOYSA-N N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide Chemical compound C=1C=C2NC(=O)C=CC2=CC=1OCCCC(=O)N(C)C1CCCCC1 UIAYVIIHMORPSJ-UHFFFAOYSA-N 0.000 claims description 3
- 206010040954 Skin wrinkling Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229940043430 calcium compound Drugs 0.000 claims description 3
- 150000001674 calcium compounds Chemical class 0.000 claims description 3
- 229950002934 cilostamide Drugs 0.000 claims description 3
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 210000004207 dermis Anatomy 0.000 claims description 3
- 210000001705 ectoderm cell Anatomy 0.000 claims description 3
- 210000004039 endoderm cell Anatomy 0.000 claims description 3
- 210000002615 epidermis Anatomy 0.000 claims description 3
- 239000003797 essential amino acid Substances 0.000 claims description 3
- 235000020776 essential amino acid Nutrition 0.000 claims description 3
- 239000003688 hormone derivative Substances 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 239000002777 nucleoside Substances 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000003716 rejuvenation Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 3
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 239000011647 vitamin D3 Substances 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 2
- 229930003448 Vitamin K Natural products 0.000 claims description 2
- 150000007513 acids Chemical group 0.000 claims description 2
- 229960005069 calcium Drugs 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- 210000002744 extracellular matrix Anatomy 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 108010082117 matrigel Proteins 0.000 claims description 2
- 239000007758 minimum essential medium Substances 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims description 2
- 229960001476 pentoxifylline Drugs 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- 229960004559 theobromine Drugs 0.000 claims description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
- 229940046010 vitamin k Drugs 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 229940100888 zinc compound Drugs 0.000 claims description 2
- 150000003752 zinc compounds Chemical class 0.000 claims description 2
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims 2
- 229940093497 ergothioneine Drugs 0.000 claims 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 125000000017 cortisol group Chemical group 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 230000008439 repair process Effects 0.000 abstract description 9
- 238000001802 infusion Methods 0.000 description 76
- 102000005962 receptors Human genes 0.000 description 41
- 108020003175 receptors Proteins 0.000 description 41
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 25
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 25
- 230000007423 decrease Effects 0.000 description 24
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 22
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 22
- 230000006872 improvement Effects 0.000 description 22
- 108010082126 Alanine transaminase Proteins 0.000 description 19
- 102000001554 Hemoglobins Human genes 0.000 description 18
- 108010054147 Hemoglobins Proteins 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 16
- 230000006378 damage Effects 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 108010001857 Cell Surface Receptors Proteins 0.000 description 12
- 102000000844 Cell Surface Receptors Human genes 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 11
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 11
- 208000002903 Thalassemia Diseases 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 230000003907 kidney function Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 108010058597 HLA-DR Antigens Proteins 0.000 description 9
- 102000006354 HLA-DR Antigens Human genes 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 238000002595 magnetic resonance imaging Methods 0.000 description 9
- 210000000689 upper leg Anatomy 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 8
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 8
- 210000004524 haematopoietic cell Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 7
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 7
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 7
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 7
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 7
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 210000000278 spinal cord Anatomy 0.000 description 7
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 6
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 6
- 208000031886 HIV Infections Diseases 0.000 description 6
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 6
- 102000043129 MHC class I family Human genes 0.000 description 6
- 108091054437 MHC class I family Proteins 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 6
- 229940072107 ascorbate Drugs 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 210000004700 fetal blood Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000004393 visual impairment Effects 0.000 description 6
- -1 2 βΜΕ Substances 0.000 description 5
- 102100027211 Albumin Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 5
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 5
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 230000000925 erythroid effect Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 210000002161 motor neuron Anatomy 0.000 description 5
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 230000002207 retinal effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000003982 Parathyroid hormone Human genes 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 206010043391 Thalassaemia beta Diseases 0.000 description 4
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 4
- 206010047571 Visual impairment Diseases 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 201000010901 lateral sclerosis Diseases 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 210000003887 myelocyte Anatomy 0.000 description 4
- 239000000199 parathyroid hormone Substances 0.000 description 4
- 229960001319 parathyroid hormone Drugs 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 229940076788 pyruvate Drugs 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 208000007056 sickle cell anemia Diseases 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 238000011476 stem cell transplantation Methods 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 208000029257 vision disease Diseases 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 206010065973 Iron Overload Diseases 0.000 description 3
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- 208000008238 Muscle Spasticity Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000013394 immunophenotyping Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- 229940040129 luteinizing hormone Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 201000008752 progressive muscular atrophy Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 238000009168 stem cell therapy Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000024806 Brain atrophy Diseases 0.000 description 2
- 229940123150 Chelating agent Drugs 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 108010074604 Epoetin Alfa Proteins 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 2
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 description 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 108010052199 HLA-C Antigens Proteins 0.000 description 2
- 108010024164 HLA-G Antigens Proteins 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 108010085682 Hemoglobin A Proteins 0.000 description 2
- 102000007513 Hemoglobin A Human genes 0.000 description 2
- 108010027616 Hemoglobin A2 Proteins 0.000 description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 2
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 2
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 description 2
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100032999 Integrin beta-3 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 101150076359 Mhc gene Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 101100011750 Mus musculus Hsp90b1 gene Proteins 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 206010060872 Transplant failure Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 201000004995 autoimmune glomerulonephritis Diseases 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 208000022806 beta-thalassemia major Diseases 0.000 description 2
- 210000002960 bfu-e Anatomy 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 102000018146 globin Human genes 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 210000003281 pleural cavity Anatomy 0.000 description 2
- 229950009829 prasterone sulfate Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000009613 pulmonary function test Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000000419 skeletal muscle satellite cell Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000009580 stem-cell therapy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 101150117196 tra-1 gene Proteins 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- GXMBHQRROXQUJS-UHFFFAOYSA-N (2-hept-2-ynylsulfanylphenyl) acetate Chemical compound CCCCC#CCSC1=CC=CC=C1OC(C)=O GXMBHQRROXQUJS-UHFFFAOYSA-N 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- RQPKNXVVIBYOBX-KDBLBPRBSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-2-(dihydroxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 RQPKNXVVIBYOBX-KDBLBPRBSA-N 0.000 description 1
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 108010044267 Abnormal Hemoglobins Proteins 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010052346 Brain contusion Diseases 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010065163 Clonal evolution Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 108010091326 Cryoglobulins Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 206010015769 Extradural haematoma Diseases 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 102100039894 Hemoglobin subunit delta Human genes 0.000 description 1
- 108091005903 Hemoglobin subunit delta Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 208000011683 Hereditary muscle disease Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101001020548 Homo sapiens LIM/homeobox protein Lhx1 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021074 Hypoplastic anaemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102100036133 LIM/homeobox protein Lhx1 Human genes 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 102100038553 Neurogenin-3 Human genes 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000011191 Pulmonary vascular disease Diseases 0.000 description 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 1
- 102100035459 Pyruvate dehydrogenase protein X component, mitochondrial Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000030934 Restrictive pulmonary disease Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 description 1
- 208000028979 Skull fracture Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DGUFGVRBHSFJGU-UHFFFAOYSA-N acetic acid ethane-1,2-diol Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.OCCO DGUFGVRBHSFJGU-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 201000006288 alpha thalassemia Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 208000022809 beta-thalassemia intermedia Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000011509 clonal analysis Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 208000006602 delta-Thalassemia Diseases 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 201000006321 fundus dystrophy Diseases 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000001995 gravitational field-flow fractionation Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001096 hypoplastic effect Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000024244 muscle cell apoptotic process Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 210000004287 null lymphocyte Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000003016 quadriplegic effect Effects 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229940001089 sinemet Drugs 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 101150108218 sox7 gene Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000004515 ventral tegmental area Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Definitions
- a method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells.
- the method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the
- the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient.
- the retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient.
- Stem cells are characterized by their ability to renew themselves through mitotic cell division and to differentiate into a diverse range of specialized cell types.
- the two broad types of mammalian stem cells are embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in adult tissues.
- stem cells can differentiate into all of the specialized embryonic tissues.
- stem cells and progenitor cells replenish specialized cells and maintain the normal turnover of regenerative organs such as blood, skin or intestinal tissues.
- Stem cells are abundant in a developing embryo, although, the quantity of stem cells decreases as development progresses.
- an adult organism contains a limited number of stem cells which are confined to certain body compartments.
- stem cells have the potential to alter treatments for multiple diseases or disorders. While some adult stem cell therapies, such as bone marrow transplants, already exist, medical researchers anticipate using stem cells to treat a wider variety of diseases including cancer, Parkinson's disease, spinal cord injuries, amyotrophic lateral sclerosis, multiple sclerosis, and muscle damage, among others. Such therapies may take advantage of the stem cells' capability of differentiating into cell types that are necessary to treat the disease.
- haematopoietic stem cells are traditionally extracted by isolation from bone marrow, growth factor mobilized peripheral blood, or cord blood (placenta).
- Haematopoietic stem cells may also be prepared from embryonic stem (ES) cells, which are extracted from embryos obtained using in vitro fertilization techniques.
- ES embryonic stem
- stem cells that may be obtained from these sources are limited. Moreover, the stem cells may experience difficulty in differentiating into the cells necessary to treat the ailment.
- the present invention relates to the use of reprogrammed cells to repair tissue or replenish tissue or cells in a patient.
- the present invention relates to the use of retrodifferentiated cells, obtained from retrodifferentiation of differentiated or committed cells, to repair tissue or replenish tissue or cells in a patient.
- the present invention also relates to the use of transdifferentiated cells, obtained from transdifferentiation of differentiated or committed cells, to repair tissue or replenish tissue or cells in a patient.
- the application is based, in part, on Applicant's discovery that committed or somatic cells obtained from a patient may be reprogrammed to result in cells of different lineages, and these reprogrammed cells can be administered to the patient to repair or replenish tissues or cells. Examples of the process of reprogramming include retrodifferentiation and transdifferentiation.
- committed cells may undergo reprogramming to result in cells of a different lineage.
- committed cells may undergo retrodifferentiation to result in retrodiffereiitiated cells, e.g., cells that are less differentiated, such as pluripotent stem cells, and that these retrodifferentiated cells can be administered to the patient to repair or replenish tissues or cells.
- retrodiffereiitiated cells e.g., cells that are less differentiated, such as pluripotent stem cells
- these retrodifferentiated cells can be administered to the patient to repair or replenish tissues or cells.
- committed cells obtained fi-om a patient may undergo transdifferentiation to result in transdifferentiated cells, e.g., cells of a different lineage than the committed cells, and that these transdifferentiated cells may be administered to the patient to repair or replenish tissues or cells.
- the invention encompasses a method of repairing or replenishing tissue or cells of a cell lineage in a patient by administering reprogrammed cells to the patient.
- the invention encompasses a method of repairing or replenishing tissue or cells of a cell lineage in a patient, comprising (i) obtaining committed cells, (ii) retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and (iii) administering the retrodifferentiated target cells to the patient, wherein the retrodifferentiated target cells redifferentiate into cells of the cell lineage.
- These redifferentiated cells may be of the same cell lineage or of a different cell lineage as the committed cells.
- the invention also encompasses a method of repairing or replenishing tissue or cells of a cell lineage in a patient, comprising (i) obtaining committed cells, (ii)
- transdifferentiating the committed cells to obtain transdifferentiated target cells, and (iii) administering the transdifferentiated target cells to the patient.
- the patient may be suffering from a disease, disorder, or condition including, but not limited to, bone marrow failure, haematological conditions, aplastic anemia, beta-thalassemia, diabetes, motor neuron disease, Parkinson's disease, spinal cord injury, muscular dystrophy, kidney disease, multiple sclerosis, congestive heart failure, hepatitis C virus, human immunodeficiency virus, head trauma, spinal cord injuries, lung disease, depression, non-obstructive azoospermia, andropause, menopause and infertility, rejuvenation, sclerodenna ulcers, psoriasis, wrinkles, liver cirrhosis, autoimmune disease, alopecia, retinitis pigmentosa, crystalline dystrophy/blindness, diabetes, and infertility.
- the reprogrammed cells may be bone marrow cells that treat aplastic anemia, leukemia, lymphoma, or human immunodefic
- the reprogrammed target cells may include, but are not limited to, pluripotent stem cells, pluripotent genu cells, haematopoietic stem cells, neuronal stem cells, epithelial stem cells, mesenchymal stem cells, endodermal and neuroectodermal stem cells, germ cells, extraembryonic, embryonic stem cells, kidney cells, alveolar epithelium cells, endoderm cells, neurons, ectoderm cells, islet cells, acinar cells, oocytes, sperm, haematopoietic cells, hepatocytes, skin/keratinocytes, melanocytes, bone/osteocytes, hair/dermal papilla cells, cartilage/chondrocytes, fats cells/adipocytes, skeletal muscular cells, endothelium cells, cardiac muscle/cardiomyocytes, and tropo
- the committed cells are obtained from blood or related tissues including bone marrow.
- the committed cells may be obtained from whole blood, and/or may be obtained through apheresis.
- the blood may be mobilized or unmobilized blood.
- Such committed cells include, but are not limited to, T cells, B cells, eosinophils, basophils, neutrophils, megakaryocytes, monocytes, erythrocytes, granulocytes, mast cells, lymphocytes, leukocytes, platelets, and red blood cells.
- the committed cells may be obtained from neuronal tissue from the central nervous system or peripheral nervous system, muscle tissue, or epidermis and/or dermis tissue from skin.
- the committed cells are obtained from the blood or tissue of a patient.
- the patient from which the committed cells are obtained, and to which the reprogrammed target cells such as retrodifferentiated target cells or the transdifferentiated target cells are administered is the same patient.
- the committed cells are retrodifferentiated by contacting the committed cells with an agent.
- the committed cells may be incubated with the agent.
- the agent engages a receptor that mediates capture, recognition or presentation of an antigen at the surface of the committed cells.
- the receptor may be an MHC class I antigen or an MHC class II antigen.
- the class I antigen is an HLA-A receptor, an F1LA-B receptor, an HLA-C receptor, an HLA-E receptor, an HLA-F receptor or an HLA-G receptor and said class II antigen is an HLA-DM receptor, an HLA-DP receptor, an HLA-DQ receptor or an HLA-DR receptor.
- the agent may be an antibody to the receptor, such as a monoclonal antibody to the receptor.
- the antibody is monoclonal antibody CR3/43 or monoclonal antibody TAL 1B5.
- the agent modulates MHC gene expression, such as MHC class I + and/or MHC class II + expression.
- the retrodifferentiated cells may undergo redifferentiation in a separate step.
- the retrodifferentiated cells may be redifferentiated by contacting the retrodifferentiated cells with growth factors including, but not limited to, basic fibroblast growth factor , epidermal growth factor, granulocyte macrophage colony- stimulating factor, stem cell factor, interleukins-l, -3, -6, and -7, basic fibroblast growth factor, epidermal growth factor, granulocyte-macrophage colony stimulating factor, granulocyte-colony stimulating factor, erythropoietin, stem cell factor, and bone
- growth factors including, but not limited to, basic fibroblast growth factor , epidermal growth factor, granulocyte macrophage colony- stimulating factor, stem cell factor, interleukins-l, -3, -6, and -7, basic fibroblast growth factor, epidermal growth factor, granulocyte-macrophage colony stimulating factor, granulocyte-colony stimulating factor,
- the resulting redifferentiated target cells may then be administered to a patient.
- the committed cells can be transdifferentiated by culturing the committed cells in particular culture conditions.
- the committed cells may be cultured in particular types of culture media in conjunction with the retrodifferentiation agents. Examples of these culture media may include Dulbecco's
- tissue culture media may also comprise differentiation promoting agent such as vitamin and/or mineral supplements, hydrocortisone, dexamethasone, ⁇ -mercaptoethanol, etc.
- additional culturing conditions include using chelating agents or antibiotics, culturing at certain temperatures or carbon dioxide or oxygen levels, and culturing in certain vessels.
- the culture conditions can determine the type of transdifferentiated target cell that results.
- One aspect of the invention is thereby a method of obtaining target cells.
- the method may comprise obtaining committed cells and then reprogramming the committed cells. These processes are as described in this application.
- the method may comprise retrodifferentiating committed cells.
- the method may comprise transdifferentiating committed cells.
- the method may comprise retrodifferentiating committed cells, and then redifferentiating the retrodifferentiated cells .
- Another aspect of the invention is use of one or more reprogrammed target cells in preparation of a medicament for repairing or replenishing tissue or cells of a cell lineage in a patient, or for treating a disease or tissue injury.
- another aspect of the invention is a method of treating a disease or tissue injury in a patient in need thereof.
- the method comprises obtaining committed cells, reprogramming the committed cells to obtain reprogrammed target cells, and administering reprogrammed target cells to the patient.
- the target cells may be reprogrammed via retrodifferentiation, transdifferentiation, and/or ⁇ differentiation.
- the target cells are retrodifferentiated target cells, transdifferentiated target cells, and/or redifferentiated target cells. The proceses of obtaining the committed cells and reprogramming the committed cells are as described in this application.
- the reprogrammed target cells such as retrodifferentiated target cells, transdifferentiated target cells, or redifferentiated target cells
- the reprogrammed target cells may be administered via injection, implantation, or infusion. These cells may be administered by parenteral, intramuscular, intravenous, subcutaneous, intraocular, oral, transdermal injection, or injection into spinal fluid.
- the retrodifferentiated target cells or transdifferentiated target cells are administered in a pharmaceutical composition.
- the pharmaceutical composition may comprise the retrodifferentiated target cells or
- transdifferentiated target cells and at least one pharmaceutically acceptable excipient.
- the pharmaceutical composition for administering the reprogrammed target cells, such as retrodifferentiated target cells or transdifferentiated target cells.
- the pharmaceutical composition may comprise one or more types of target cells, and at least one pharmaceutically acceptable carrier.
- the pharmaceutical composition may include adjuvants and/or other excipients suitable for administration into a patient.
- Another aspect of the invention is a method of preparing a pharmaceutical composition or medicament comprising (i) obtaining committed cells, (ii) reprogramming the committed cells to obtain reprogrammed target cells, and (iii) optionally, combining the reprogrammed target cells with one or more pharmaceutical excipients.
- the reprogrammed target cells are combined with one or more pharmaceutical excipients. In other embodiments, the reprogrammed target cells are not combined with one or more pharmaceutical excipients.
- the processes of obtaining committed cells and reprogramming the committed cells are as described in this application.
- FIG. 1 shows immunophenotyping of aphaeresed mononuclear cells before (top panel) and after (lower panel) induction of reprogramming.
- Cells were labeled with monoclonal antibodies conjugated to R-phycoerythrin (RPE) Cy-5 or phycoerythrins (PE) (vertical legends) for immunoglobulin Gl (IgGl) isotype control and CD34 or CD19, respectively.
- RPE R-phycoerythrin
- PE phycoerythrins
- IgGl immunoglobulin Gl
- Cells were also stained for CD45, CD38, CD61 , and IgGl isotype controls monoclonal antibodies conjugated to fluorescein isothiocyanate (FITC) (horizontal legends).
- Lower panel show increase in haematopoietic stem cells as depicted by in crease in the relative number of CD34 and CD34CD38- cells accompanied by decrease in leukocyte
- FIG. 2a shows sequential immunophenotyping of peripheral blood samples of a patient with severe aplastic anemia following infusion of autologous HRSC (post Day 1, Day 2, Day 3, Day 6, and Day 14).
- Cells were labeled with monoclonal antibodies against CD34 and CD45 (2 nd horizontal panel), and CD34 and CD38 (3 rd horizontal panel).
- the top horizontal panel shows forward and side scatter is flow cytometry, bone marrow smear, and tehphin section of autologous HRSC.
- Dayl to Day 14 shows an increase in cells having large forward and side scatter that is indicative of granulocytes
- Dayl to Day3 shows an increase in the relative number of circulating CD34 haematopoietic stem cells.
- FIG. 1 shows sequential immunophenotyping of peripheral blood samples of a patient with severe aplastic anemia following infusion of autologous HRSC (post Day 1, Day 2, Day 3, Day 6, and Day 14).
- Cells were labeled with monoclonal antibodies against CD34 and CD
- FIG. 2b shows sequential immunophenotyping of peripheral blood samples of a patient with severe aplastic anemia following infusion of autologous human reprogrammed stem cell (HRSC) (post Day 1, Day 2, Day 3, Day 6, and Day 14).
- HRSC autologous human reprogrammed stem cell
- Cells were labeled with monoclonal antibodies against CD34 and CD61 (1 st horizontal panel), CD19 and CD3 (2 nd panel), and CD33&13 and CD7 (3 rd horizontal panel).
- the FACScan plots show increase in the number of myeloid cells, as depicted by a gradual increase in cells expressing CD33&13 including progenitor cells, which is depicted by an increase in the relative number of cell co- expressing CD33&13 with CD7. Also, there was a gradual increase in the relative number of lymphocytes, as shown by an increase in the relative number of CD 19 and CD3 lymphocytes.
- FIG. 3 shows bone marrow analysis of a severe aplastic anaemia patient before and after infusion of autologous HRSC.
- Bone marrow smear before and after therapy shows increase in red blood cells; terphine section before and after therapy (c and d) shows increase in bone marrow cellularity; clonal analysis of bone marrow following infusion of HRSC showing increased growth of colony forming unit megakarocyte (e); colony forming monocyte (f); colony forming granulocyte and macrophage (g); and colony forming myelocyte and erytliroid (h); and burst forming erythroid (i).
- colony forming unit megakarocyte e
- colony forming monocyte f
- colony forming granulocyte and macrophage g
- colony forming myelocyte and erytliroid h
- burst forming erythroid i
- FIG. 4 shows karyotyping and g-banding of peripheral blood sample of a patient with severe aplastic anemia following 4 years of infusion with autologous HRSC showing no genetic abnormalities.
- FIG. 5 shows increase in absolute mean fetal hemoglobin levels in patients with thalassemia, post-treatment with autologous reprogrammed cells.
- FIG. 6 shows increase in mean corpuscular volume, which represents the average size of red blood cells, expressed in femtoliters, in patients with thalassemia, post-treatment with autologous reprogrammed cells.
- FIG. 7 shows increase in mean cell hemoglobin, which is the weight of the hemoglobin per cell, expressed in picograms, in patients with thalassemia, post-treatment with autologous reprogrammed cells.
- FIG. 8 shows decrease in serum ferritin levels, expressed in nanograms per milliliter, in patients with thalassemia, post-treatment with autologous reprogrammed cells.
- FIG. 9 shows increase in C-peptide levels fasting and post mixed meal diet intake in patients with diabetes, post-treatment with autologous reprogrammed cells.
- FIG. 10 shows decrease in glycosylated hemoglobin (HbAlC) levels in patients with diabetes, post-treatment with autologous reprogrammed cells.
- HbAlC glycosylated hemoglobin
- FIG. 11 shows decrease in creatine phosphokinase (CPK) and lactate dehydrogenase (LDH) levels in patients with muscular dystrophy, post- treatment with autologous reprogrammed cells.
- FIG. 12 shows decrease in liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients with muscular dystrophy, post-treatment with autologous reprogrammed cells.
- CPK creatine phosphokinase
- LDH lactate dehydrogenase
- FIG. 13 shows decrease in microalbumin urea levels in 12 patients with kidney disease, post-treatment with autologous reprogrammed cells.
- FIG. 14 shows decrease in glycosylated hemoglobin (HbAlC) levels in 12 patients with kidney disease due to diabetes, post-treatment with autologous reprogrammed cells.
- HbAlC glycosylated hemoglobin
- FIG. 15a shows magnetic resonance imaging (MRI) scans of the brain of a patient with multiple sclerosis before (left scan) and three months after (right scan) treatment with autologous reprogrammed cells depicting decrease in lesion enhancement post stem cell therapy.
- FIG. 15b shows MRI scans of a different part of the brain of the patient before (left scan) and three months after (right scan) treatment with autologous reprogrammed cells.
- the arrows point to a lesion in the brain, while in the scans depicting after treatment, the arrows point to the improvement in the lesion.
- FIG. 16a shows magnetic resonance imaging (MRI) scans of the brain of a patient with multiple sclerosis before (top scans) and six months after (bottom scans) treatment with autologous reprogrammed cells.
- FIG. 16b shows additional MRI scans of the brain of the patient before (top scans) and six months after (bottom scans) treatment with autologous reprogrammed cells.
- the arrows point to a lesion in the brain, while in the scans depicting after treatment, the arrows point to the improvement in the lesion with reduction in brain atrophy as depicted by reduction in ventricle and sulci dilatation.
- FIG. 17a shows sagittal magnetic resonance imaging (MRI) scans of a patient with multiple sclerosis before (left scan) and six months after (right scan) treatment with autologous reprogrammed cells.
- FIG. 17b shows transverse MRI scans of the spinal cord of the patient before (left scan) and six months after (right scan) treatment with autologous reprogrammed cells.
- the arrows point to a lesion on the spinal cord, while in the scans depicting after treatment, the arrows point to the improvement in the lesion.
- FIG. 18a shows decrease liver enzymes alanine aminotransferase (ALT) levels
- FIG. 18b shows decrease in aspartate aminotransferase (AST) levels in patients infected with hepatitis C, post-treatment with autologous reprogrammed cells
- FIG. 19a shows magnetic resonance imaging (MRI) scans of the brain of a patient with head trauma due to a motor accident. Before treatment (top scans), the ventricles show dilatation and displacement with a wide speared haematoma. After treatment with autologous reprogrammed cells (bottom scans), the ventricles show decrease in brain atrophy parameters such as reduction in ventricle and sulci dilatation with amelioration of haematoma.
- FIG. 19b shows additional MRI scans of the brain of the patient before (top scans) and after (bottom scans) treatment.
- FIG. 20 shows chest x-rays of a patient with lung disease before (left x-ray) and after (right x-ray) treatment with autologous reprogrammed cells. After treatment, the patient shows improvement in lung volume and reduction in lesion size as depicted by decrease in hypo-dense areas.
- FIG. 21 shows sex hormone levels for follicle-stimulating hormone (fsh), luteinizing hormone (lh), progesterone (pro), and testosterone (test) in patients with non-obstructive azoospermia and treated with autologous reprogrammed cells.
- the levels show significant increase in free testosterone with an increase in testis size (data not shown) determined by ultrasound.
- FIG. 22 shows retinal sensitivity and visual impairment in a patient suffering from impaired vision before (top panel) and after (bottom panel) treatment with autologous reprogrammed cells.
- the orange area indicates decreased retinal sensitivity.
- the white areas indicate normal vision and the pink, orange, and black areas indicate increased visual impairment.
- the patient experienced improvement in his visual field, as orange areas in the retinal sensitivity results before treatment turned green and white after treatment, and black areas in the visual impairment results before treatment turned white after treatment.
- mitted cells are cells that display a differentiated character. These cells are often considered mature and specialized. Examples include white blood cells, red blood cells, epithelial cells, neurons, and chondrocytes.
- uncommitted cells are cells that do not display a mature differentiated character. These cells are often considered immature and are not specialized.
- An example of an uncommitted cell is a stem cell, which is an immature cell that is capable of self-renewal (division without limit) and differentiation (specialization).
- reprogramming refers to a process by which a committed cell of a first cell lineage is changed into a cell of a different cell type. This different cell type may be of a different cell lineage. Reprogramming may occur through such processes as retrodifferentiation, transdifferentiation, or redifferentiation.
- a "reprogrammed cell” is a cell that underwent reprogramming of a committed cell.
- a reprogrammed cell may include a retrodifferentiated cell,
- transdifferentiated cell and/or a redifferentiated cell.
- “retrodifferentiation” is the process by which a committed cell, i.e., mature, specialized cell, reverts back to a more primitive cell stage.
- “Retrodifferentiated cell” is a cell that results from retrodifferentiation of a committed cell.
- transdifferentiation is the process by which a committed cell of a first cell lineage is changed into another cell of a different cell type.
- transdifferentiation may be a combination of retrodifferentiation and redifferentiation.
- Transdifferentiated cell is a cell that results from transdifferentiation of a committed cell.
- a committed cell such as a whole blood cell may be transdifferentiated into a neuron.
- redifferentiation refers to the process by which an uncommitted cell or a retrodifferentiated cell differentiates into a more mature, specialized cell.
- Redifferentiated cell refers to a cell that results from redifferentiation of an uncommitted cell or a retrodifferentiated cell. If a redifferentiated cell is obtained through redifferentiation of a retrodifferentiated cell, the redifferentiated cell may be of the same or different lineage as the committed cell that had undergone retrodifferentiation. For example, a committed cell such as a white blood cell may be retrodifferentiated to form a
- retrodifferentiated cell such as a pluripotent stem cell
- the retrodifferentiated cell may be redifferentiated to form a lymphocyte, which is of the same lineage as the white blood cell (committed cell), or redifferentiated to form a neuron, which is of a different lineage than the white blood cell (committed cell).
- target cell is a cell that is obtained for administration into a patient to repair or replenish tissue or cells.
- a target cell may be a reprogrammed target cell, such as a retrodifferentiated target cell or a transdifferentiated target cell, whereby the retrodifferentiated or transdifferentiated target cell is administered to the patient.
- committed cells of the invention are cells that display a differentiated character.
- the committed cell may comprise any components that are concerned with antigen presentation, capture or recognition.
- the committed cell may be an MHC Class I + and/or an MHC Class II + cell.
- the committed cell may also be any cell derived or derivable from an
- the committed cell is also an
- the committed cell can be a lymphoid stem cell or a myeloid stem cell, which is differentiated relative to a pluripotent stem cell.
- Committed cells may be derived from biological material, such as blood or related tissues including bone marrow or cord blood, neuronal tissue from the central nervous system or peripheral nervous system, muscle tissue, or epidermis and/or beis tissue from skin (i.e. by way of oral scraping for instance).
- biological material may be of post-natal origin.
- the biological material may be obtained using methods known in the art that are suitable for the tissue type. Examples include, but are not limited to, excision, needle withdrawal, swabbing, and apheresis.
- the committed cells are derived from whole blood or processed products thereof, such as plasma or the buffy coat, since their removal from subjects can be carried out with the minimum of medical supervision.
- Blood samples are typically treated with anticoagulants such as heparin or citrate.
- Cells in the biological sample may be treated to enrich certain cell types, remove certain cell types or dissociate cells from a tissue mass.
- Useful methods for purifying and separating cells include centrifugation (such as density gradient centrifugation), flow cytometry and affinity chromatography (such as the use of magnetic beads comprising monoclonal antibodies to cell surface markers or panning) (see Vettese-Dadey, The Principle 1999, 13: 21).
- Ficoll-Hypaque separation is useful for removing erythrocytes and granulocytes to leave mononuclear cells such as lymphocytes and monocytes.
- Examples of committed cells that can be derived from blood include, but are not limited to, CFC-T cells, CFC-B cells, CFC-Eosin cells, CFC-Bas cells, CFC-Bas cells, CFC-GM cells, CFC-M, CFC-MEG cells, BFC-E cells, CFC-E cells, T cells, B cells, eosinophils, basophils, neutrophils, monocytes, megakaryocytes, and erythrocytes.
- Blood derived committed cells may be identified by their expression of particular antigens.
- B cells are CD19 + , CD21 + , CD22 + and DR + cells.
- T cells are CD2 + , CD3 + , and either CD4 + or CD8 + cells.
- Immature lymphocytes are CD4 + and CD8 + cells.
- Activated T cells are DR + cells.
- Natural killer cells (NKs) are CD56 + and CD16 + cells.
- T lymphocytes are CD7 cells.
- Leukocytes are CD45 cells.
- Granulocytes are CD13 + and CD33 + cells.
- Monocyte macrophage cells are CD14 + and DR + cells.
- the committed cell may be a B lymphocyte (activated or non-activated), a T lymphocyte (activated or non-activated), a cell from the macrophage monocyte lineage, a nucleated cell capable of expressing class I or class II antigens, a cell that can be induced to express class I or class II antigens or an enucleated cell (i.e. a cell that does not contain a nucleus—such as a red blood cell).
- the committed cell may be selected from any one of a group of cells comprising large granular lymphocytes, null lymphocytes and natural killer cells, each expressing the CD56 and/or CD 16 cell surface receptors.
- the committed cells are essentially primary cultures, it may necessary to supplement populations of cells with suitable nutrients to maintain viability. Suitable culture conditions are known by the skilled person in the art. Nonetheless, treatment of cell populations is preferably initiated as soon as possible after removal of biological samples from patients, typically within 12 hours, preferably within 2 to 4 hours. Cell viability can be checked using well known techniques such as trypan blue exclusion or propidium iodide.
- Retrodifferentiation is a type of a reprogramming process whereby structures and functions of cells are progressively changed to give rise to less specialized cells.
- Retrodifferentiation can occur naturally, wherein cells may undergo limited reverse differentiation in vivo in response to tissue damage. Alternatively, retrodifferentiation may be induced using the methods described in U.S. application Serial No. 08/594,164, now U.S.
- Retrodifferentiated cells of the invention may include, but are not limited to pluripotent stem cells, lymphoid stem cells, myeloid stem cells, neural stem cells, skeletal muscle satellite cells, epithelial stem cells, endodermal stem cells, mesenchymal stem cells, and embryonic stem cells.
- the committed cells are derived from blood and are retrodifferentiated to form retrodifferentiated cells of the haematopoietic cell lineage.
- retrodifferentiated cells examples include, but are not limited to, pluripotent stem cells, lymphoid stem cells, and myeloid stem cells.
- Committed cells may be retrodifferentiated by contacting the cells with an agent that operably engages the cells. The cells are then incubated so as to allow those cells that have been operably engaged by the agent to progress tlirough the retrodifferentiation process and ultimately become undifferentiated.
- the contacting step may comprise the agent engaging with surface antigens on the committed cell.
- the agent may act in direct engagement or in indirect engagement with the committed cell.
- An example of direct engagement is when the committed cell has at least one cell surface receptor on its cell surface, such as a ⁇ -chain having homologous regions (regions that are commonly found having the same or a similar sequence) such as those that may be found on B cells, and wherein the agent directly engages the cell surface receptor.
- Another example is when the committed cell has a cell surface receptor on its cell surface such as an a-chain having homologous regions such as those that may be found on T cells, and wherein the agent directly engages the cell surface receptor.
- An example of indirect engagement is when the committed cell has at least two cell surface receptors on its cell surface and engagement of the agent with one of the receptors affects the other receptor which then induces retrodifferentiation of the committed cell.
- the agent for the retrodifferentiating the committed cell may be a chemical compound or composition.
- the agent may be capable of engaging a cell surface receptor on the surface of the committed cell.
- the agent operably engages a receptor present on the surface of the committed cell - which receptor may be expressed by the committed cell, such as a receptor that is capable of being expressed by the committed cell.
- agents may include, but are not limited to, any one or more of cyclic adenosine monophosphate (cAMP), a CD4 molecule, a CD8 molecule, a part or all of a T- cell receptor, a ligand (fixed or free), a peptide, a T-cell receptor (TCR), an antibody, a cross-reactive antibody, a monoclonal antibody, or a polyclonal antibody.
- Growth factors may also be used, such as haematopoietic growth factors, for example erythropoietin and granulocyte-monocyte colony stimulating factor (GM-CSF).
- the agent may be any one or more of an antibody, a cross-reactive antibody, a monoclonal antibody, or a polyclonal antibody to any one or more of: the .beta, chain of a MHC class II antigen, the ⁇ -chain of a MHC HLA-DR antigen, the a-chain of a MHC class I or class II antigen, the a-chain of HLA-DR antigen, the a- and the ⁇ -chain of MHC class II antigen or of a MHC class I antigen.
- An example of an antibody is CR3/43 (supplied by Dako).
- antibody may include the various fragments (whether derived by proteolytic cleavage or recombinant technology) and derivatives that retain binding activity, such as Fab, F(ab') 2 and scFv antibodies, as well as mimetics or bioisosteres thereof. Also included as antibodies are genetically engineered variants where some of the amino acid sequences have been modified, for example by replacement of amino acid residues to enhance binding or, where the antibodies have been made in a different species to the organism whose cells it is desired to treat according to the methods of the invention, to decrease the possibility of adverse immune reactions (an example of this is "humanized' mouse monoclonal antibodies).
- Agents used to effect the conversion of a committed cell to a retrodifferentiated cell preferably may act extracellularly of the committed cell.
- the committed cell may comprise a receptor that is operably engageable by the agent and the agent operably engages the receptor.
- the receptor may be a cell surface receptor.
- cell surface receptors include, but are not limited to, MHC class I and class II receptors.
- the receptor may comprise an a-component and/or a ⁇ -component, as is the case for MHC class I and class II receptors.
- the receptor may comprises a ⁇ -chain having homologous regions, for example at least the homologous regions of the ⁇ -chain of HLA-DR.
- the receptor may comprise an a-chain having homologous regions, for example at least the homologous regions of the a-chain of HLA- DR.
- the receptor may be a Class I or a Class II antigen of the major histocompatibility complex (MHC).
- MHC major histocompatibility complex
- the cell surface receptor may include, but are not limited to, an HLA-DR receptor, a DM receptor, a DP receptor, a DQ receptor, an HLA-A receptor, an HLA-B receptor, an HLA-C receptor, an HLA-E receptor, an HLA-F receptor, or an HLA-G receptor.
- the cell surface receptor may be an HLA-DR receptor.
- the agent may be an antibody to the receptor, such as a monoclonal antibody to the receptor.
- An example of an agent may be one that modulates MHC gene expression such as MHC Class I + and/or MHC Class IF " expression.
- the agent may be used in conjunction with a biological response modifier.
- biological response modifiers include, but are not limited to, an alkylating agent, an immunomodulator, a growth factor, a cytokine, a cell surface receptor, a hormone, a nucleic acid, a nucleotide sequence, an antigen or a peptide.
- an alkylating agent may be or may comprise cyclophosphoamide.
- Other biological response modifiers may include compounds capable of upregulating
- MHC class I and/or class II antigen expression which, in some embodiments, may allow an agent that binds to an MHC receptor to work more effectively.
- any cell type can be made to express MHC class I and/or class II antigens, this may provide a method for retrodifferentiating a wide variety of cell types whether they constitutively express class I and/or class II MHC antigens or not.
- Committed cells are generally incubated with an agent for at least two hours, typically between 2 and 24 hours, preferably between 2 and 12 hours. Incubations are typically performed at from about room temperature or for example about 22° C, up to about 37° C, including 33° C.
- the progress of the retrodifferentiating procedure can be checked periodically by removing a small aliquot of the sample and examining cells using microscopy and/or flow cytometry.
- the device can comprise tracking means for on-line monitoring the progress of the retrodifferentiating procedure.
- the committed cells may be cultured in autologous plasma or serum, or in fetal blood serum or horse serum.
- the committed cells may be cultured with anticoagulants, chelating agents, or antibiotics.
- the temperature range for incubating the cells may be extended to 18-40 °C, and may also include 4-10 % C0 2 and/or 10-35 % 0 2 .
- incubation may occur in blood bags, tissue culture bags, or plastic vessels, which are coated or uncoated.
- retrodifferentiated cells may be obtained by retrodifferentiating using particular culture conditions.
- committed cells may be retrodifferentiated into pluripotent cells by culturing the committed cells in Dulbecco's Modified Eagle Medium (DMEM), non-essential amino acids (NEAA), L-glutamine (L-glu), and ⁇ - mercaptoethanol (2 ⁇ ), in conjunction with the retrodifferentiating agents.
- DMEM Dulbecco's Modified Eagle Medium
- NEAA non-essential amino acids
- L-glu L-glutamine
- ⁇ - mercaptoethanol (2 ⁇ ) ⁇ -mercaptoethanol
- committed cells may be cultured - in conjunction with retrodifferentiating agent(s) - using DMEM (low glucose) and L-glu, or DMEM (low glucose), L-glu, 2 ⁇ , and NEAA.
- DMEM low glucose
- L-glu low glucose
- DMEM low glucose
- NEAA low glucose
- the antibiotic gentamycin may also be used in the cell culture.
- Transdifferentiated cells are obtained by culturing committed cells with a tissue culture media in conjunction with retrodifferentiating agents.
- the committed cells thereby undergo transdifferentiation, wherein the committed cells are transformed to cells of another cell type; in some embodiments, the committed cells are transformed to cells of a different lineage.
- the type of target cell obtained through transdifferentiation is dependent on the culturing conditions. These conditions vary according to the type of tissue culture media, the presence/absence of various differentiation promoting agents, the presence/absence of different serums, the incubation temperature, the presence/absence of oxygen or carbon dioxide, and the type of container or vessel used for incubation.
- tissue culture media used for transdifferentiation include, but are not limited to, Iscove's Modified Dulbecco's Medium (IMDM), Dulbecco's Modified Eagle Medium (DMEM), Eagle's minimum essential (EME) medium, alpha- minimum essential medium ( ⁇ - ⁇ ), Roswell Park Memorial Institute (RPMI; site where medium was developed) 1640, Ham-F-12, El 99, MCDB, Leibovitz L-15, Williams Medium E, or any commercially formulated tissue culture medium.
- IMDM Iscove's Modified Dulbecco's Medium
- DMEM Dulbecco's Modified Eagle Medium
- EME Eagle's minimum essential
- RPMI Roswell Park Memorial Institute
- Differentiation promoting agents include anticoagulants, chelating agents, and antibiotics.
- agents may be one or more of the following: vitamins and minerals or derivatives thereof, such as A (retinol), B 3 , C (ascorbate), ascorbate 2- phosphate, D 2 , D 3 , K, retinoic acid, nicotinamide, zinc or zinc compound, and calcium or calcium compounds; natural or synthetic hormones such as hydrocortisone, and
- dexamethasone amino acids or derivatives thereof, such as L-glutamine (L-glu), ethylene glycol tetracetic acid (EGTA), proline, and non-essential amino acids (NEAA); compounds or derivatives thereof, such as ⁇ -mercaptoethal, dibutyl cyclic adenosine monophosphate (db-cAMP), monothioglycerol (MTG), putrescine, dimethyl sulfoxide (DMSO),
- amino acids or derivatives thereof such as L-glutamine (L-glu), ethylene glycol tetracetic acid (EGTA), proline, and non-essential amino acids (NEAA); compounds or derivatives thereof, such as ⁇ -mercaptoethal, dibutyl cyclic adenosine monophosphate (db-cAMP), monothioglycerol (MTG), putrescine, dimethyl sulfoxide (DMSO),
- db-cAMP dibutyl cyclic adeno
- hypoxanthine adenine, forskolin, cilostamide, and 3-isobutyl-l-methylxanthine
- nucleosides and analogues thereof such as 5-azacytidine
- acids or salts thereof such as ascorbic acid, pyruvate, okadic acid, linoleic acid, ethylenediaminetetraacetic acid (EDTA), anticoagulant citrate dextrose formula A (ACDA), disodium EDTA, sodium butyrate, and
- glycerophosphate glycerophosphate
- antibiotics or drugs such as G418, gentamycine, Pentoxifylline (l-(5- oxohexyl)-3, 7-dimethylxanthine), and indomethacin
- proteins such as tissue plasminogen activator (TP A).
- differentiation promoting agents may be used to obtain particular types of target cells.
- vitamin B 3 may be used to yield acinar cells such as islet cells or hydrocortisone; dexamethasone may be used to yield cells of mesenchymal origin or epithelial origins (e.g. kidney epithelial cells, skin and associated structures such as dermal papilla cells); and ⁇ -mercaptoethal may be used to yield ectodermal cells such as neuronal cells, including accessory cells of the CNS.
- the culture medium may contain autologous plasma; platelets; serum such as fetal blood sampling; or sera of mammalian origin such as horse serum. Furthermore, the conversion process can occur inside blood bags, scaffolds, tissue culture bags, or plastic tissue culture vessels.
- the tissue culture vessels may be adherent or non-adherent tissue culture vessels, or may be coated or uncoated with agents such as gelatin, collagen, matrigels or extracellular matrices that either promote adherence or floatation depending on the required type of tissue or specialized cells to be prepared.
- Additional culturing conditions include the temperature, which may be between about 10 and about 60 °C, or between about 18 and about 40 °C; levels of carbon dioxide (C0 2 ), which may be between about 0 and about 20 %, or about 4 and about 10 %; and oxygen (0 2 ), which may be between about 0 and about 50 %, or about 10 and about 35 %.
- C0 2 carbon dioxide
- oxygen (0 2 ) oxygen
- Medium 199 can be used as a basal medium instead
- hydrocortisone optionally with
- hydrocortisone hydrocorbate
- Haematopoietic e IMDM optionally with • Incubation can be at 33 °C cells hydrocortisone; or e Incubation can be at room
- Culture conditions for • differentiated cells can be pluripotent stem cells listed exposed to chelating agents prior above, with MTG substituted for to conversion in order to amplify 2 ⁇ , optionally with vitamins for erythroid progenitors in culture
- RPMI 1640 can be used as a basal medium for enrichment of lymphoid progenitors
- Sodium butyrate and/or 5- azacytidine can be added to culture to promote primitive erythroid differentiation
- liver essential medium L-glu
- hydrocortisone optionally with hydrocortisone
- dexamethasone, L-glutamine and • Can be with low serum sodium pyruvate; or concentration.
- DMEM and Ham F12 or F10 as • Can be with culture vessels with basal medium, or DMEM and gelatin
- NEAA NEAA
- DMEM low glucose
- the culture medium optionally containing the various components
- differentiation promoting agents may be diluted by the addition of more medium but without the retrodifferentiating agent.
- dilution seems to increase differentiation because cells become less dense and proliferation stimulating factors are less concentrated.
- the addition of medium may further enhance transdifferentiation and will affect what type of cell within the cell lineage is obtained. For instance, if the target cell is a neuron, the addition of culture medium may result in a shift in development towards a more mature neuron rather than a neuron progenitor (both are of the same lineage).
- forward differentiation skeletal muscle progenitors will only differentiate by consecutive dilution of culture medium which is achieved by gradually decreasing the serum concentration.
- the retrodifferentiated cells may be used to obtain target cells by recommitting or redifferentiating the retrodifferentiated cells to a target cell type. This may be performed by contacting the retrodifferentiated cells with growth factors. For example, retinoic acid has been used to differentiate stem cells into neuronal cells. Methylcellulose followed by co- culture with a bone marrow stromal line and IL-7 has been used to differentiate stem cells into lymphocyte precursors (Nisitani et al., Int Immuno 1994, 6: 909-916). Le Page (New Scientist Dec. 16, 2000) teaches that stem cells can be differentiated into lung epithelial cells.
- Neural precursor cells can be expanded with basic fibroblast growth factor and epidermal growth factor (Nakafuku and Nakamura, J Neurosci Res 1995, 41 : 153-168).
- Haematopoietic stem cells can be expanded using a number of growth factors including GM-CSF, erythropoietin, stem cell factor and interleukins (IL-1 , IL-3, IL-6)— see Metcalf (Nature 1989, 339: 27-30) for a review of these various factors.
- the redifferentiated cell may be of the same lineage as the committed cell from which the retrodifferentiated cell was derived.
- the redifferentiated cell may be of a different lineage than the committed cell from which the retrodifferentiated cell was derived.
- a B lymphocyte may be retrodifferentiated to a CD34 + CD38 " HLA- DR " stem cell. This stem cell may be subsequently redifferentiated or recommitted along a B cell lineage (the same lineage) or a lymphoid lineage (different lineage).
- target cells of the invention are reprograrnmed cells that can be obtained by retrodifferentiation, transdifferentiation, or redifferentiation as described above.
- target cells may include, but are not limited to, pluripotent stem cells, lymphoid stem cells, myeloid stem cells, neural stem cells, skeletal muscle satellite cells, epithelial stem cells, endodermal and neuroectodermal stem cells, germ cells,
- extraembryonic and embryonic stem cells mesenchymal stem cells, , kidney cells, alveolar epithelium cells, endoderm cells, neurons, ectoderm cells, islet cells, acinar cells, oocytes, sperm, haematopoietic cells, hepatocytes, skin/keratinocytes, melanocytes, bone/osteocytes, hair/dermal papilla cells, cartilage/chondrocytes, fats cells/adipocytes, skeletal muscular cells, endothelium cells, cardiac muscle/cardiomyocytes, and tropoblasts.
- committed cells and/or retrodifferentiated cells are cultured under particular conditions to induce retrodifferentiation and/or transdifferentiation and/or redifferentiation and obtain the target cells.
- the duration for which the committed cells and/or retrodifferentiated cells are cultured is not controlled by a particular length of time, but rather by a determination that the target cells have been produced. The determination of the production of, or the changes in the number of,
- retrodifferentiated, transdifferentiated, or redifferentiated target cells may be performed by monitoring changes in the relative number of committed cells that downregulates expression of lineage-associated markers or transcription factors, and/or changes in the relative number of cells having cell surface markers characteristic of the target cells. Alternatively, or in addition, decreases in the numbers of cells having cell surface markers typical of the committed cells and not the target cells may be monitored.
- the target cell may be an embryonic stem cell, which are characterized by many stage-specific markers such as POU5F1 (OCT-4), TERT, KLF4, UTFl , SOX2, Nanog or stage-specific embryonic markers 3 and 4 (SSEA-3 and SSEA-4), high molecular weight glycoproteins TRA- 1 -60 and TRA- 1 - 81 and alkaline phosphatase (Andrews et al., Hybridoma 1984, 3: 347-361 ; Kannagi et al., EMBO J 1983, 2: 2355-2361 ; Fox et al., Dev Biol 1984, 103: 263-266; Ozawa et al., Cell Differ 1985, 16: 169-173).
- stage-specific markers such as POU5F1 (OCT-4), TERT, KLF4, UTFl , SOX2, Nanog or stage-specific embryonic markers 3 and 4 (SSEA-3 and SSEA-4), high molecular weight glycoproteins TRA- 1
- SSEA-1 SSEA-1
- Other markers are known for other types of stem cells, such as Nestein for neuroepithelial stem cells (J Neurosci 985, 5: 3310).
- Mesenchymal stem cells are positive for SH2, SH3, CD29, CD44, CD71, CD90, CD106, CD120a and CD124, for example, and negative for CD34, CD45 and CD14.
- Pluripotent stem cells are CD34 + DR " TdT " cells (other useful markers being CD38 " and CD36 + ).
- Lymphoid stem cells are DR + , CD34 + and TdT + cells (also CD38 + ).
- Myeloid stem cells are CD34 + , DR + , CD13 + , CD33 + , CD7 + and TdT + cells.
- Additional cell markers for target cells may be discovered through microarray analysis.
- the analysis may involve isolating RNA from target cells that were
- the microarray may comprise genes or oligonucleotides representing a whole genome, or may comprise genes or oligonucleotides directed to a particular organ system, tissue system, disease, pathology, etc.
- Cell markers may be identified by which genes/oligonucleotides exhibit high signal intensity, and are thereby upregulated or downregulated in the target cells. This information can then be applied to determining target cells based on the presence of markers, or even groups or a partem of markers, that were identified by the microarray analysis.
- Confirmation of target cells can also be performed using a number of in vitro assays such as CFC assays (see also, the examples).
- Very primitive haematopoietic stem cells are often measured using the long-term culture initiating cell (LTC-IC) assay (Eaves et al, J Tiss Cult Meth 1991, 13: 55-62). LTC-ICs sustain haemopoiesis for 5 to 12 weeks.
- LTC-IC long-term culture initiating cell
- cell culturing may continue until the target cells emerge as characterized by immunohistochemistry, flow cytometry, microarrays, or reverse-transcription polymerase chain reaction (RT-PCR), which are techniques known in the art.
- RT-PCR reverse-transcription polymerase chain reaction
- This may also include functional assays, for example, engrafting an immunodeficient host or correcting or ameliorating an underlying clinical condition, as observed herein.
- the target cells can be identified by microarray or RT-PCR that show acquisition of new lineage-specific transcription factors, proteins, and signals in the target cells.
- retrodifferentiated stem cells converted to target cells of the ectodermal lineage may express genes such as Nestin, Criptol, isll, LHX1, and/or EN1, and if further differentiated into neurons, will be expressing neurofilaments (NF).
- cells converted into target cells of the endodermal lineage may express genes such as sox7, soxl 7, Nodal, PDX1, and/or FOXA2; but target cells further differentiated towards pancreatic islet cells may express genes such as insulin (INS) and neurog3 (NGN3).
- INS insulin
- NTN3 neurog3
- the conversion towards the desired target cells may be accompanied by down regulation of mature transcription factors associated with the original starting population that has undergone conversion.
- the determination of the production of target cells may occur by recognizing particular structural and/or morphological characteristics of the target cells, e.g., cell shape, size, etc. These characteristics are known in the art for the target cells of the invention.
- the resulting altered cell populations may be used in a number of ways.
- target cells e.g., pluripotent stem cells
- the numbers of target cells or other retrodifferentiated cells formed may appear to be low, studies have shown that only 50 pluripotent haematopoietic stem cells can reconstitute an entire haematopoietic system in a donor mouse. Thus therapeutic utility does not require the formation of a large number of cells.
- Conversion of committed cells to retrodifferentiated, transdifferentiated, or redifferentiated target cells may also be carried out in vivo by administration of the agent, admixed with a pharmaceutically carrier or diluent, to a patient. However it is preferred in many cases that retrodifferentiating, transdifferentiating, or redifferentiating is performed in vitro lex vivo.
- Treated populations of cells obtained in vitro may be used subsequently with minimal processing. For example they may be simply combined with a pharmaceutically acceptable carrier or diluent and administered to a patient in need of stem cells.
- the retrodifferentiated, transdifferentiated, or redifferentiated target cells may be desirable to enrich the cell population for the retrodifferentiated, transdifferentiated, or redifferentiated target cells or purify the cells from the cell population.
- This can conveniently be performed using a number of methods (see Vattese-Dadey ⁇ The Engineer 1999, 13).
- cells may be purified on the basis of cell surface markers using chromatography and/or flow cytometry. Nonetheless, it will often be neither necessary nor desirable to extensively purify retrodifferentiated, transdifferentiated, or redifferentiated target cells from the cell population since other cells present in the population (for example stromal cells) may maintain stem cell viability and function.
- the purification or isolation means may comprise a flow cytometer.
- Flow cytometry operates on the basis of physical characteristics of particles in liquid suspension, which can be distinguished when interrogated with a beam of light. Such particles may of course be cells. Physical characteristics include cell size and structure or, as has become very popular in recent years, cell surface markers bound by monoclonal antibodies conjugated to fluorescent molecules.
- Visser et al. (Blood Cells 1980, 6:391-407) teach that stem cells may be isolated on the basis of their size and degree of structuredness.
- Grogan et al. (Blood Cells 1980, 6: 625-44) also teach that "viable stem cells may be sorted from simple haematopoietic tissues in high and verifiable purity".
- cell populations may be enriched, purified using negative criteria.
- cells that possess lineage specific markers such as CD4, CD8, CD42 and CD3 may be removed from the cell population by flow cytometry or affinity chromatography.
- a very useful technique for purifying cells involves the use of antibodies or other affinity ligands linked to magnetic beads.
- the beads are incubated with the cell population and cells that have a cell surface marker, such as CD34, to which the affinity ligand binds are captured.
- the sample tube containing the cells is placed in a magnetic sample concentrator where the beads are attracted to the sides of the tube. After one or more wash stages, the cells of interest have been partially or substantially completely purified from other cells.
- the liquid phase is kept and consequently, the cells bound to the beads are effectively removed from the cell population.
- Cell populations comprising reprogrammed target cells such as retrodifferentiated, transdifferentiated, or redifferentiated target cells, and/or purified reprogrammed target cells, such as retrodifferentiated, transdifferentiated, or redifferentiated target cells produced by the methods of the invention, may be maintained in vitro using known techniques.
- minimal growth media such as Hanks, RPMI 1640, Dulbecco's Minimal Essential Media (DMEM) or Iscove's Modified Dulbecco Medium
- mammalian serum such as FBS
- autologous plasma mammalian serum
- Stem cells may be cultured on feeder layers such as layers of stromal cells (see Deryugina et al. Crit Rev Immunology 1993, 13: 1 15-150). Stromal cells are believed to secrete factors that maintain progenitor cells in an undifferentiated state.
- a long term culture system for stem cells is described by Dexter et al. (J Cell Physiol 1977, 91 : 335) and Dexter et al. (Acta Haematol 1979, 62: 299).
- Lebkowski et al. (Transplantation 1992, 53: 1011-9) teaches that human CD34 + haematopoietic cells can be purified using a technology based on the use of monoclonal antibodies that are covalently immobilized on polystyrene surfaces and that the CD34 + cells purified by this process can be maintained with greater than 85% viability.
- Lebkowski et al. (J Hematother 1993, 2: 339-42) also teaches how to isolate and culture human CD34 + cells. See also Haylock et al. (Immunomethods 1994, 5: 217-25) for a review of various methods. Cell populations comprising stem cells and purified preparations comprising stem cells may be frozen/cryopreserved for future use. Suitable techniques for freezing cells and subsequently reviving them are known in the art.
- the retrodifferentiating, transdifferentiating, or ⁇ differentiating occurs to cells from or in buffy coat blood samples.
- buffy coat means the layer of white cells that forms between the layer of red cells and the plasma when unclotted blood is centrifuged or allowed to stand.
- Reprogrammed target cells of the present invention may be combined with various components to produce compositions of the invention.
- the compositions may be combined with one or more pharmaceutically acceptable carriers or diluents to produce a pharmaceutical composition (which may be for human or animal use).
- Suitable carriers and diluents include, but are not limited to, isotonic saline solutions, for example phosphate- buffered saline.
- the composition of the invention may be administered by direct injection.
- the composition may be formulated for parenteral, intramuscular, intravenous,
- Compositions comprising target cells may be delivered by injection or implantation.
- Cells may be delivered in suspension or embedded in a support matrix such as natural and/or synthetic biodegradable matrices.
- Natural matrices include, but are not limited to, collagen matrices.
- Synthetic biodegradable matrices include, but are not limited to, polyanhydrides and polylactic acid. These matrices may provide support for fragile cells in vivo.
- compositions may also comprise the retrodifferentiated or transdifferentiated or redifferentiated target cells of the present invention, and at least one pharmaceutically acceptable excipient, carrier, or vehicle.
- Delivery may also be by controlled delivery, i.e., delivered over a period of time which may be from several minutes to several hours or days. Delivery may be systemic (for example by intravenous injection) or directed to a particular site of interest. Cells may be introduced in vivo using liposomal transfer.
- Target cells may be administered in doses of from 1 x 10 5 to 1 x 10 7 cells per kg.
- a 70 kg patient may be administered 14 x 10 6 CD34 + cells for reconstitution of tissues.
- the dosages may be any combination of the target cells listed in this application.
- the methods of the invention can be used to treat a variety of diseases, conditions, or disorders. Such conditions include, but are not limited to, bone marrow failure,
- haematological conditions aplastic anemia, beta-thalassemia, diabetes, motor neuron disease, Parkinson's disease, spinal cord injury, muscular dystrophy, kidney disease, liver disease, multiple sclerosis, congestive heart failure, hepatitis C virus, human
- azoospermia andropause, menopause and infertility, rejuvenation, scleroderma ulcers, psoriasis, wrinkles, liver cirrhosis, autoimmune disease, alopecia, retinitis pigmentosa, and crystalline dystrophy/blindness or any disorder associated with tissue degeneration.
- Aplastic anemia is a rare but fatal bone marrow disorder, marked by pancytopaenia and hypocellular bone marrow (Young et al. Blood 2006, 108: 2509-2519).
- the disorder may be caused by an immune-mediated pathophysiology with activated type I cytotoxic T cells expressing Thl cytokine, especially ⁇ -interferon targeted towards the haematopoietic stem cell compartment, leading to bone marrow failure and hence anhaematoposis
- graft failure winch may ensue weeks or months after stem cell transplantation (Gottdiener et al., Arch Intern Med 1981, 141 : 758- 763; Sanders et al. Semin Hematol 1991, 28: 244-249). Moreover the risk of graft failure increases with the number of blood transfusion received prior stem cell transplantation.
- Thalassaemia is an inherited autosomal recessive blood disease marked by a reduced synthesis rate of one of the globin chains that make up hemoglobin. Thus, there is an underproduction of normal globin proteins, often due to mutations in regulatory genes, which results in formation of abnormal hemoglobin molecules, causing anemia.
- Different types of thalassemia include alpha thalassemia, beta thalassemia, and delta thalassemia, which affect production of the alpha globin, beta globin, and delta globin, respectively.
- Treatments include chronic blood transfusion, iron chelation, splenectomy, and allogeneic haematopoietic transplantation. However, chronic blood transfusion is not available to most patients due to the lack of an HLA-matched bone marrow donor, while allogeneic hematopoietic transplantation is associated with many possible complications such as infections and graft-versus-host disease.
- Diabetes is a syndrome resulting in abnormally high blood sugar levels
- Diabetes refers to a group of diseases that lead to high blood glucose levels due to defects in either insulin secretion or insulin action in the body. Diabetes is typically separated into two types: type 1 diabetes, marked by a diminished production of insulin, or type 2 diabetes, marked by a resistance to the effects of insulin. Both types lead to hyperglycemia, which largely causes the symptoms generally associated with diabetes, e.g., excessive urine production, resulting compensatory thirst and increased fluid intake, blurred vision, unexplained weight loss, lethargy, and changes in energy metabolism.
- Diabetes is considered to be a chronic disease, without a cure.
- Treatment options are limited to insulin injections, exercise, proper diet, or, for patients who have type 2 diabetes, some medications, e.g., those that promote insulin secretion by the pancreas, decrease glucose produced by the liver, increase sensitivity of cells to insulin, etc.
- Motor neuron diseases refer to a group of neurological disorders that affect motor neurons. Such diseases include amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), and progressive muscular atrophy (PMA). ALS is marked by degeneration of both the upper and lower motor neurons, which ceases messages to the muscles and results in their weakening and eventual atrophy. PLS is a rare motor neuron disease affecting upper motor neurons only, which causes difficulties with balance, weakness and stiffness in legs, spasticity, and speech problems. PMA is a subtype of ALS that affects only the lower motor neurons, which can cause muscular atrophy, fasciculations, and weakness. There are no known cures for motor neuron diseases.
- ALS amyotrophic lateral sclerosis
- PLS primary lateral sclerosis
- PMA progressive muscular atrophy
- Riluzole which is believed to reduce damage to motor neurons, has been has approved as a medication for ALS, although it slows down the progression of ALS rather than improves its effects.
- treatments only address symptoms, such as baclofen which can reduce spasticity or quinine which may decrease cramps.
- Parkinson's disease is a neurodegenerative disorder marked by the loss of the nigrostriatal pathway, resulting from degeneration of dopaminergic neurons within the substantia nigra.
- the cause of PD is not known, but is associated with the progressive death of dopaminergic (tyrosine hydroxylase (TH) positive) mesencephalic neurons, inducing motor impairment.
- TH dopaminergic
- PD is characterized by muscle rigidity, tremor, bradykinesia, and potentially akinesia.
- Symptomatic treatment of the disease-associated motor impairments involves oral administration of dihydroxyphenylalanine (L-DOPA), which can lead to a substantial improvement of motor function, but its effects are reduced as the degeneration of dopaminergic neurons progresses.
- Alternative strategies include neural grafting, which is based on the idea that dopamine supplied from cells implanted into the striatum can substitute for lost nigrostriatal cells, and gene therapy, which can be used to replace dopamine in the affected striatum by introducing the enzymes responsible for L-DOPA or dopamine synthesis such as by introducing potential neuroprotective molecules that may either prevent the TH-positive neurons from dying or stimulate regeneration and functional recovery in the damaged nigrostriatal system.
- Spinal cord injury is characterized by damage to the spinal cord and, in particular, the nerve fibers, resulting in impairment of part or all muscles or nerves below the injury site. Such damage may occur through trauma to the spine that fractures, dislocates, crushes, or compresses one or more of the vertebrae, or through nontraumatic injuries caused by arthritis, cancer, inflammation, or disk degeneration. While treatments following spinal cord injury may involve medications such as methylprednisolone, which is a corticosteroid that reduce damage to nerve sells and decreases inflammation in the injured area, or medications that control pain and muscle spasticity, as well as immobilization of the spine or surgery to remove herniated disks or any objects that may be damaging the spine, there is no known means to reverse the damage to the spinal cord.
- methylprednisolone which is a corticosteroid that reduce damage to nerve sells and decreases inflammation in the injured area, or medications that control pain and muscle spasticity, as well as immobilization of the spine or surgery to remove herniated
- MD Muscular dystrophy
- Kidney disease refers to conditions that damage the kidneys and decrease their ability to function, which includes removal of wastes and excess water fro the blood, regulation of electrolytes, blood pressure, acid-base balance, and reabsorption of glucose and amino acids.
- the two main causes of kidney disease are diabetes and high blood pressure, although other causes include glomerulonephritis, lupus, and malformations and obstructions in the kidney.
- There is no cure for kidney disease, and thereby therapy focuses on slowing the progression of the disease and treating the causes of the disease, such as through controlling blood glucose and high blood pressure and monitoring diet; treating complications of the disease, for example, by addressing fluid retention, anemia, bone disease; and replacing lost kidney function, such as through dialysis or transplantation.
- MS multiple sclerosis is an autoimmune condition in which the immune system attacks the central nervous system, leading to demyelination.
- MS affects the ability of nerve cells in the brain and spinal cord to communicate with each other, as the body's own immune system attacks and damages the myelin which enwraps the neuron axons. When myelin is lost, the axons can no longer effectively conduct signals. This can lead to various neurological symptoms which usually progresses into physical and cognitive disability.
- treatments attempt to return function after an attack (sudden onset or worsening of MS symptoms), prevent new attacks, and prevent disability. For example, treatment with corticosteroids may help end the attack, while treatment with interferon during an initial attack has been shown to decrease the chance that clinical MS will develop.
- HIV Human immunodeficiency virus
- AIDS acquired immunodeficiency syndrome
- HIV primarily infects vital cells in the human immune system such as helper T cells, macrophages, and dendritic cells. HIV infection leads to low levels of CD4 + T cells by direct viral killing of infected cells, by increased rates of apoptosis in infected cells, or by killing of infected CD4 + T cells by CD8 cytotoxic lymphocytes that recognize infected cells.
- Treatment for HIV infection consists of highly active antiretroviral therapy, or HAART.
- NARTIs nucleoside analogue reverse transcriptase inhibitors
- RTI non- nucleoside reverse transcriptase inhibitor
- Congestive heart failure refers to a condition in which the heart cannot pump enough blood to the body's other organs. This condition can result from coronary artery disease, scar tissue on the heart cause by myocardial infarction, high blood pressure, heart valve disease, heart defects, and heart valve infection.
- Treatment programs typically consist of rest, proper diet, modified daily activities, and drugs such as angiotensin-converting enzyme (ACE) inhibitors, beta blockers, digitalis, diuretics, vasodilators. However, the treatment program will not reverse the damage or condition of the heart.
- ACE angiotensin-converting enzyme
- Hepatitis C is an infectious disease in the liver, caused by hepatitis C virus. Hepatitis C can progress to scarring (fibrosis) and advanced scarring (cirrhosis). Cirrhosis can lead to liver failure and other complications such as liver cancer.
- Current treatments include use of a combination of pegylated interferon alpha and the antiviral drug ribavirin. Success rates can vary between 50-80% depending on the virus genotype.
- Head trauma refers to an injury of the head that may or may not cause injury to the brain.
- head trauma includes traffic accidents, home and occupational accidents, falls, and assaults.
- Various types of problems may result from head trauma, including skull fracture, lacerations of the scalp, subdural hematoma (bleeding below the dura mater), epidural hematoma (bleeding between the dura mater and the skull), cerebral contusion (brain bruise), concussion (temporary loss of function due to trauma), coma, or even death.
- Treatment for head trauma will vary with the type of injury. If the brain is damaged, there is no quick means to fix it, and often the damage may be irreversible by available treatment means.
- Lung disease is a broad term for diseases of the respiratory system, which includes the lung, pleural cavity, bronchial tubes, trachea, upper respiratory tract, and nerves and muscles for breathing.
- lung diseases include obstructive lung diseases, in which the bronchial tubes become narrowed; restrictive or fibrotic lung diseases, in which the lung loses compliance and causes incomplete lung expansion and increased lung stiffness; respiratory tract infections, which can be caused by the common cold or pneumonia; respiratory tumors, such as those caused by cancer; pleural cavity diseases; and pulmonary vascular diseases, which affect pulmonary circulation.
- Treatment for lung disease varies according to the type of disease, but can include medication such as corticosteroids and antibiotics, oxygen, mechanical ventilation, radiotherapy, and surgery.
- Depression is a mental disorder characterized by a low mood accompanied by low self-esteem and loss of interest or pleasure in normally enjoyable activities.
- Biologically depression is accompanied by altered activity in multiple parts of the brain, including raphe nuclei, which are a group of small nuclei in the upper brain stem that is a source of serotonin; suprachiasmatic nucleus, which controls biological rhythms such as the sleep/wake cycle; hypothalamic-pituitary-adrenal axis, which is a chain of structures that are activated during the body's response to various stressors; ventral tegmental area, which is considered to be responsible for the "reward" circuitry of the brain; nucleus accumbens, which us thought to play a role in reward, laughter, pleasure, addiction, and fear; and the anterior cingulated cortex, which is activated by negative experiences.
- Treatments for depression include antidepressants that increase the amount of extracellular serotonin in the brain, exercise, and psychotherapy.
- Non-obstructive azoospermia is a medical condition of a male not having any measureable level of sperm in his semen due to a problem with spermatogenesis. This is often caused by hormonal imbalance and can be treated using medications which restore the imbalance.
- Andropause is a menopause- like condition experienced in middle-aged men, which involves a reduction in the production of the hormones testosterone and
- Treatments include hormone replacement therapy and exercise.
- Scleroderma is a chronic autoimmune disease that affects comiective tissue.
- Hardening of the skin is the most visible manifestation of the disease, although it can affect connective tissue throughout the body. There is no known direct cure for scleroderma.
- Psoriasis is a chronic autoimmune disease that causes red, scaly patches to appear on the skin. The cause is psoriasis is linked to the excessive growth of skin cells.
- T-cells which migrate to the dermis and trigger the release of cytokines that induce the rapid production of skin cells.
- Treatments for psoriasis include drugs that target the T-cells.
- Retinitis pigmentosa is type of progressive retinal dystrophy in which the photoreceptors or the retinal pigment epithelium is abnormal and leads to visual loss.
- the conditions described herein may be treated with a particular type, or a combination of types, of target cells.
- the condition described herein may be treated by infusion of the cell types outlined in Table 2. Table 2.
- Treatment regimes of various conditions using reprogrammed, i.e., retrodifferentiated or transdifferentiated or redifferentiated, target cells Autoimmune Disease mesenchymal stem cells and/or pluripotent stem cells
- a patient may be treated for a condition as described above through the following steps:
- Fistula-cannula is inserted in a patient's arm
- White blood cells are harvested through aphaeresis using an automated system, such as the COBE ® Spectra Device (Gambro PCT);
- the autologous retrodifferentiated stem cells are washed and then infused intravenously into the patient;
- Patient's progress is monitored, including taking blood tests and assessing the injured areas.
- This clinical study assessed the safety of infusing a single dose of autologous 3 hr reprogrammed cells following exposure to haematopoietic inductive culture condition into four patients with aplastic anemia.
- the patients were transfused with 2 units of irradiated packed red blood cells and 4 units of platelets to maintain their hemoglobin level above 8 g/dl and platelets counts above 50,000.
- Patient were apheresed by processing 2-3 times their total blood volume using the Cobe Spectra apheresis machine and the white blood cells separation kit (both from Gambro BCT). Apheresis involved jugular and anticubetal venous catheterization with single lumen catheter for venous access.
- Table 4 Clinical and treatment history of aplastic anemia patients up to Autologous human reprogrammed stem cell (HRSC) infusion.
- HRSC Autologous human reprogrammed stem cell
- Table 5 Patient, date of infusion, weight and height, mononuclear cells collect and CD34+ cell infused.
- Panel 1 consisted of Isotype negative control IgGl-FITC, IgGl-PE-Cy5 and IgGl- PvPE conjugates
- Panel 2 consisted of anti-human CD45-FITC and CD34-RPE-Cy5
- Panel 3 consisted of anti-human CD38-FITC and CD34-RPE-Cy5
- Panel 4 consisted of CD61-FITC and CD34-RPE-Cy5
- Panel 5 consisted of CD33/13 RPE and CD7-FITC
- Panel 6 consisted of CD45 and Glycophorin-A-RPE
- Panel 7 consisted of CD3-FITC and CD19-RPE
- bone marrow mononuclear cells (M C) of patient prior and post infusion of the reprogrammed cells were seeded into methocult GFH4434 supplemented with recombinant growth factors according to the manufacturer's instructions (Stem Cell Technologies). Differentiation into haematopoietic cell colonies was assessed and scored with time using phase contrast inverted microscopy.
- CBC liver enzymes and haemoglobin variants were continuously monitored before and post procedure. Following release from hospital patients, CBC, liver enzymes, hemoglobin variants, and peripheral blood karyotyping and G banding were monitored by an independent laboratory for reconfirmation purposes. These tests were performed frequently following infusion of the autologous reprogrammed cells.
- Peripheral blood samples and bone marrow cells were analyzed before and following infusion of the autologous reprogrammed cells. This test was repeated in six-month intervals for the first year and on a yearly basis following 2 years post-initiation of autologous reprogrammed stem cell therapy. In addition, reprogrammed cells were analyzed prior infusion to look into the stability of the cells, which was also performed following the 3hr conversion step, as well as post-establislunent of a maximum 1 month long term culture of the converted cells. Karyotyping and G banding were monitored by a third independent laboratory.
- Bone marrow smears and trephine section was performed before and post infusion of the autologous reprogrammed cells. This test was performed 14-20 days post infusion of the autologous reprogrammed cells and thereafter on a yearly basis. All smear and trephine sections were scanned using a microscope hooked to a camcorder before and following infusion of the reprogrammed stem cells to assess and keep record of engraftment.
- Liver enzymes started to normalize post infusion of RHSC and reached normal levels 4 years post infusion of RHSC.
- Patient B and Patient C died 2 years and six months post infusion, respectively.
- Fetal Hb switching was noted in patients 001 and 004 (see Tables 6 and 7). These two patients exhibited long term engraftment post single infusion of the autologous HRSC.
- WBC white blood cell
- HB hemoglobin
- RBC red blood cell
- RETIC reticulocyte
- MCV mean corpuscular volume
- MCH mean corpuscular hemoglobin
- MCHC mean corpuscular hemoglobin concentration
- ESO eosinophils
- BASO basophils
- LYMPH lymphocytes
- MONO monocytes
- HB A hemoglobin A
- HBA2 hemoglobin A2; HBF
- SGOT serum glutamic oxaloacetic transaminase
- Table 7 Patient D's complete blood counts, hemoglobin variant and liver enzymes of a severe aplastic anemia patient before and after in fusion of autologous HRSC.
- MCV mean corpuscular volume
- MCH mean corpuscular hemoglobin
- MCHC mean corpuscular hemoglobin concentration
- ESO eosinophils
- BASO basophils
- LYMPH lymphocytes
- MONO monocytes
- HB A hemoglobin A
- HBA2 hemoglobin A2
- HBF fetal hemoglobin
- SGOT serum glutamic oxaloacetic transaminase
- SGPT serum glutamic pyruvic transaminase
- FIG. 1 Flow cytometry of aphaeresed mononuclear cells before and 3 hrs post induction of haematopoietic reprogramming are shown in FIG. 1.
- the number of CD34 positive cell generated post haematopoietic reprogramming is listed in Table 4.
- a representative flow cytometry of apheresed mononuclear before and post haematopoietic reprogramming show significant increase in the number of CD34 positive cells with and without expression of CD45, CD38 and CD7 (FIG. 1).
- the CD34 cells circulated peripheral blood for 3-6 days and thereafter differentiated at a sustainable level into myelocyte as depicted by significant increase in cells expressing CD33&13 with and without CD7 having high forward and side scatter (see FIG. 2). Tins pattern of reprogramming was observed in all patients.
- Hb F haemoglobin level (Tables 6 and 7). This was not noted in the other 2 patients that died. Hb F switching in these two patients confirms the reprogramming capabilities of the infused H SC towards juvenile Hb phenotype and hence engraftment and reconstitution as observed with cord blood stem cells transplant (Elhasid et al., Leukemia 2000, 14: 931-934; Locatelli et al, Bone Marrow Transplant 1996, 18: 1095-101).
- the autologous HRSC were capable of long term engraftment and survival rate in a subset of severe aplastic anaemia patients without use of any
- reprogrammed cells have exhibited a normal karyotype and genetic stability after infusion. Finally, engraftment and long term repopulation was observed in 3 more patient suffering from aplastic anemia.
- beta thalassemia Autologous reprogrammed haematopoietic cells (target cells) were tested in 21 patients with beta thalassemia. Nineteen patients had beta-thalassemia major and 2 had thalassemia intermedia. One of the beta thalassemia intermedia patient was thalassemia/Hb E variant (common in patient of far eastern and Indian origin) and the other had
- the autologous reprogrammed cells were generated through reprogramming white blood cells until the target cells were obtained, as indicated by their distinguishing characteristics as described above.
- the patients were administered the autologous reprogrammed cells via intravenous infusion into the jugular or veins in the arm or thigh.
- the mean weight and height following infusion of the reprogrammed cells were significantly greater when compared to base line, and the organ size in thalassemic patients with enlarged spleen and/or liver was normalized.
- the absolute mean fetal haemoglobin concentration significantly increased in patients with thalassemia major and intermedia following infusion of the reprogrammed cells when compared to baseline (FIG. 5).
- the mean red blood cell indices as reflected by improvement in red blood cell size haemoglobin content (FIG. 6) and concentration (FIG. 7) was also significantly improved as compared to baseline.
- iron overload is the major cause of mortality and morbidity in patients with thalassemia; sickle cell anaemia and any transfusional iron overload induced disorder.
- Autologous reprogrammed mesenchymal stem cells, pluripotent stem cells, and islet cells (target cells) were obtained through reprogramming apheresed white blood cells until the target cells developed, as indicated by their distinguishing characteristics as described above.
- the patients were administered the autologous reprogrammed cells via intravenous infusion into the jugular or veins in the arm or thigh.
- ALS amyotrophic lateral sclerosis
- Autologous reprogrammed pluripotent stem cells, alveolar epithelium cells, and neurons (target cells) were obtained through reprogramming apheresed white blood cells until the target cells developed, as indicated by their distinguishing characteristics as described above.
- the patients were administered the autologous reprogrammed cells via intravenous infusion into the jugular or veins in the arm or thigh.
- PFT Pulmonary Function test
- Autologous reprogrammed pluripotent stem cells and neurons were obtained through reprogramming apheresed white blood cells until the target cells developed, as indicated by their distinguishing characteristics as described above. .
- the patients were administered the autologous reprogrammed cells via intravenous infusion into the jugular or veins in the arm or thigh.
- Autologous retrodifferentiated pluripotent stem cells and neurons were obtained through reprogramming apheresed white blood cells until the target cells developed, as indicated by their distinguishing characteristics as described above.
- the patients were administered the autologous reprogi'ammed cells via intravenous infusion into the jugular or veins in the arm or thigh.
- MD Muscular Dystrophy
- target cells were obtained through reprogramming apheresed white blood cells until the target cells developed, as indicated by their distinguishing characteristics as described above.
- the first patient was inflicted with limb-girdle MD, which refers to a class of MD wherein the muscles that are most severely affected generally those of the hips and shoulders, and the second patient was inflicted with nemelin MD.
- the autologous reprogrammed cells were generated through reprogramming in accordance to the invention.
- the patients were administered the autologous reprogrammed cells via intravenous infusion into the jugular or veins in the arm or thigh.
- the muscle atrophy associated with MD can be measured by monitoring the level of the muscle enzyme creatine phosphokinase (CPK). This enzyme decreased in response to infusion of the retrodifferentiated stem cells (FIG. 11). Lactate dehydrogenase, an enzyme which is elevated during tissue breakdown, also decreased (FIG. 11). Patients also experienced a decrease in liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are both associated with inflammation and injury to liver cells, as well as skeletal muscle.
- CPK creatine phosphokinase
- ALT alanine aminotransferase
- AST aspartate aminotransferase
- patients showed an improvement in patient mobility as determined by cam recording of patients before and following infusion of the reprogrammed cells, and in pulmonary function test following infusion of the reprogrammed cells when compared to baseline
- kidney disease Patients with kidney disease were treated with autologous reprogrammed pluripotent stem cells, mesenchymal stem cells, and kidney cells (target cells) were obtained through reprogramming apheresed white blood cells until the target cells developed, as indicated by their distinguishing characteristics as described above.
- the patients were apheresed by processing 2-3 times their total blood volume.
- the autologous reprogrammed cells were generated through reprogramming in accordance to the invention.
- the patients were administered the autologous reprogrammed cells via intravenous infusion into the jugular or veins in the arm or thigh.
- kidney function such as urine output, serum creatinine and BUN or UREA.
- fluid marker levels indicative of healthier kidney function
- a 75 -year old diabetic male patient showed improved kidney function 24 months after treatment with the autologous reprogrammed cells ⁇ see Table 8).
- the patient showed increased levels in hemoglobin, which is the protein molecule in red blood cells that carries oxygen, and insulin-like growth factor- 1 (IGF-1), a growth factor.
- IGF-1 insulin-like growth factor- 1
- urea which is an organic compound
- creatinine which is a breakdown product of creatine phosphate in muscle
- uric acid which is an organic compound excreted in urine
- phosphorus which is a mineral found in bone
- HbAlC hemoglobin
- a 51 -year old diabetic male exhibited similar improvement 12 months after treatment ⁇ see Table 8).
- This patient showed increased levels of hemoglobin and decreased levels of creatinine, HbAlC, and blood urea nitrogen (BUN), which is a measurement of the amount of nitrogen in the blood in the form of urea.
- BUN blood urea nitrogen
- Table 8 Kidney function marker levels in two diabetic male patients.
- HbAlC glycosylated hemoglobin
- IGF-1 Insulin-like Growth Factor 1
- BUN blood urea nitrogen
- FIG. 13 Analysis of 12 patients having Type II diabetes and treated with autologous reprogrammed cells revealed decreased levels of microalbumin (FIG. 13), which is associated with leakage of albumin into the urine and is an indicator of kidney disease, well as vascular endothelial dysfunction and cardiovascular disease. The 12 patients also experienced decreased levels of HbAlC (FIG. 14).
- Table 9 Kidney function marker levels in 45-year old female patient suffering from autoimmune glomerulonephritis.
- BUN blood urea nitrogen
- Kidney function marker levels in 45-year old female patient suffering from autoimmune The patient also decreased in the number of hemodialysis sessions that she attended per month, from 12 sessions to about 8 sessions.
- Table 10 Kidney function marker levels in 59-year old female patient suffering from end stage renal disease before and after therapy with reprogrammed cells.
- TLC total leukocyte count
- WBC white blood cells
- PLT platelet
- HbAlC glycosylated hemoglobin
- AST aspartate aminotransferase
- ALT alanine
- PT pro-thrombin time
- IN international normalized ratio(for blood coagulation)
- PTH parathyroid hormone
- a 46-year old patient suffering from chronic renal failure due to diabetes also showed improvement in creatinine level, urea, and hemoglobin level upon treatment with reprogrammed cells ⁇ see Table 11).
- the patient decreased in the number of hemodialysis sessions that he attended per month, from 12 sessions to about 5 sessions, and decreased in treatment with epoetin alfa (EPREX ® ) delivered subcutaneously, from 4000 units twice a week to 4000 units once every two weeks.
- EPREX ® epoetin alfa
- TLC total leukocyte count
- WBC white blood cells
- PP post prandial
- PLT platelet
- FBS fasting blood sugar
- AST aspartate aminotransferase
- ALT alanine
- Patients with multiple sclerosis were treated with autologous reprogrammed pluripotent stem cells, mesenchymal stem cells, and neurons (target cells).
- the target cells were through reprogramming apheresed white blood cells until the target cells developed, as indicated by their distinguishing characteristics as described above.
- the patients were apheresed by processing 2-3 times their total blood volume.
- the autologous reprogrammed cells were generated through reprogramming in accordance to the invention.
- the patients were administered the autologous reprogrammed cells via intravenous infusion into the jugular or veins in the arm or thigh.
- Patients treated with autologous reprogrammed cells showed reduction in lesions in the brain and in the spinal cord. A reduction in lesions can occur within three months of receiving the treatment (FIGS. 15a-b). A reduction in damage to brain tissue occurred within six months (FIGS. 16a-b).
- the patient was apheresed by processing 2-3 times her total blood volume.
- the target cells were obtained through reprogramming apheresed white blood cells until the target cells developed, as indicated by their distinguishing characteristics as described above.
- the patient was administered the autologous reprogrammed cells via intravenous infusion into the jugular or veins in the arm or thigh.
- the screening test for HIV-1 and HIV-2 antibodies showed a test value of 3.68. A value of 1.0 or greater is considered positive.
- test value for the HIV-1 and HIV-2 antibody screening was 0.46, which indicated that the patient did not show a positive result for HIV-1 and HIV-2.
- test value for the HIV-1 and HIV-2 screening was 0.48, further demonstrating that the patient was not showing a positive result for HIV.
- the effects of treating with autologous reprogrammed cells are demonstrated in patients suffering from other conditions and diseases.
- the target cells listed herein were obtained through reprogramming apheresed white blood cells until the target cells developed, as indicated by their distinguishing characteristics as described above
- EF ejection fraction
- Pro BNP brain natriuretic peptide precursor levels
- the heart which was previously dilated, returned to normal size as evidenced in Table 12 by decrease in end-diastolic left ventricular internal dimension (LVID/D), end-diastolic left ventricular internal dimension (LVID/S), and end-diastolic intraventricular septal thickness (IVSD) as measured by echocardiogram.
- LVID/D end-diastolic left ventricular internal dimension
- LVID/S end-diastolic left ventricular internal dimension
- IVSD end-diastolic intraventricular septal thickness
- LVID/D end-diastolic left ventricular internal dimension
- LVID/S end systolic left ventricular internal dimension
- EF ejection fraction
- IVSD end-diastolic intraventricular septal thickness
- LVPWD end-diastolic left ventricular posterior wall thickness
- Pro-BNP precursor of brain natriuretic peptide
- HbAlC glycosylated hemoglobin
- HCV hepatitis C virus
- AST aspartate aminotransferase
- WBC white blood cells
- PP post prandial
- ALT alanine aminotransferase
- AST aspartate aminotransferase
- INR international normalized ratio (for blood coagulation)
- PT prothrombin time
- a 44-year old male patient suffering from liver cirrhosis due to hepatitis C virus infection also showed improvement in liver enzymes alanine aminotransferase and aspartate aminotransferase, the international normalized ratio (for blood coagulation), bilirubin, and albumin, as well as random blood sugar ⁇ see Table 15).
- this patient was on albumin treatment before the therapy with reprogrammed cells, but did not receive albumin after the therapy.
- Table 15 Blood markers in a 44-year old male patient suffering from liver cirrhosis due to hepatitis C virus infection at baseline and after therapy with reprogrammed cells.
- TLC total leukocyte count
- PLT platelet
- AST aspartate aminotransferase
- GGT gamma-glutamyl transferase
- RBS random blood
- INR international normalized ratio (for blood coagulation) Head Trauma
- a patient suffering head trauma from a motor accident was treated with an infusion of autologous reprogrammed pluripotent stem cells and neurons.
- a patient suffering from restrictive lung disease associated with a motor neuron disease was treated with an infusion of autologous reprogrammed pluripotent stem cells, mesenchymal stem cells, alveolar epithelium cells, and endothelium cells.
- forced vital capacity FVC
- FEVi forced expiratory volume in 1 second
- the ratio of FEVi to FVC which is approximately 75-80 % in healthy adults, decreased from 100 % to 82 %.
- An x-ray scan of the lungs shows less opacity of the lung cavity after treatment (FIG. 20).
- a 51 -year old patient in menopause was administered an infusion of autologous reprogrammed pluripotent stem cells, pluripotent germ cells, and oocytes. Following the treatment, the patient experienced an increase in various hormone and protein levels, including insulin-like growth factor (IGF-1), esterdiaol, and low-density lipoprotein (LDL) (see Table 16). Table 16. Effects of administering patient in menopause with autologous reprogrammed stem cells.
- IGF-1 insulin-like growth factor
- LDL low-density lipoprotein
- a patient suffering from depression was treated with an infusion of autologous reprogrammed pluripotent stem cells and neurons. Following the treatment, the patient experienced an increase in various hormone and protein levels, including insulin-like growth factor- 1 (IGF-1), Cortisol, and testosterone (see Table 17). Table 17. Effects of administering patient in menopause with autologous reprogrammed cells.
- IGF-1 insulin-like growth factor- 1
- Cortisol cortisol
- testosterone see Table 17
- GH growth hormone
- IGF-1 insulin- like growth factor 1
- IGF-bp insulin-like growth factor binding protein
- Adrenocort adrenocortical hormone
- Sh-bg sex hormone-binding globulin
- FSH follicle- stimulating hormone
- LH luteinizing hormone
- e2 estradiol
- DHEA-S dehydroepiandrosterone sulfate ester
- TSH thyroid stimulating hormone
- FT3 free triiodothryronine
- FT4 free thyroxine
- a patient suffering from non-obstructive azoospermia was treated with an infusion of autologous reprogrammed pluripotent stem cells, pluripotent germ cells, and sperm.
- a patient suffering from vision loss due to a benign tumor that had been removed was treated with an infusion of autologous reprogrammed pluripotent stem cells and neurons. Following treatment, the patient experienced increased retinal sensitivity and improvement in vision (FIG. 22).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2009/051396 WO2011048350A1 (en) | 2009-10-19 | 2009-10-19 | Treatment using reprogrammed mature adult cells |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2490702A1 true EP2490702A1 (en) | 2012-08-29 |
Family
ID=42199514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09736651A Withdrawn EP2490702A1 (en) | 2009-10-19 | 2009-10-19 | Treatment using reprogrammed mature adult cells |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP2490702A1 (en) |
JP (1) | JP6073135B2 (en) |
KR (1) | KR101766203B1 (en) |
CN (1) | CN102647989A (en) |
AU (1) | AU2009354350B2 (en) |
CA (1) | CA2781522A1 (en) |
CH (1) | CH704227B1 (en) |
CU (1) | CU24006B1 (en) |
IL (1) | IL218902A (en) |
MA (1) | MA33740B1 (en) |
MX (1) | MX2012004522A (en) |
RU (1) | RU2635317C2 (en) |
TN (1) | TN2012000157A1 (en) |
UA (1) | UA109265C2 (en) |
WO (1) | WO2011048350A1 (en) |
ZA (1) | ZA201202664B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170296595A1 (en) * | 2014-09-18 | 2017-10-19 | North Carolina State University | Mammalian Lung Spheroids and Lung Spheroid Cells and Uses Thereof |
JP6113133B2 (en) | 2014-11-06 | 2017-04-12 | 日本メナード化粧品株式会社 | Stem cell undifferentiated state maintenance agent and growth promoter |
IL300420B1 (en) | 2015-10-16 | 2024-05-01 | Univ Columbia | Compositions and methods for inhibition of lineage specific antigens |
CN107114355A (en) * | 2016-08-01 | 2017-09-01 | 北京世纪劲得生物技术有限公司 | A kind of fat cell protection liquid and preparation method thereof |
CN110662554A (en) * | 2017-02-28 | 2020-01-07 | Vor生物制药股份有限公司 | Compositions and methods for inhibiting lineage specific proteins |
CN109731012A (en) * | 2017-10-30 | 2019-05-10 | 邹兆中 | It improves biological immune and treats the active method of active principle |
CN109706119B (en) * | 2018-04-13 | 2020-11-27 | 诺未科技(北京)有限公司 | Culture system and method for expanding hematopoietic stem cells and application thereof |
SG11202101994XA (en) | 2018-08-28 | 2021-03-30 | Vor Biopharma Inc | Genetically engineered hematopoietic stem cells and uses thereof |
KR20200025210A (en) * | 2018-08-29 | 2020-03-10 | 주식회사 스템모어 | Composition for culturing dermal papilla cells and the method for culturing dermal papilla cells using the same |
WO2021240204A1 (en) * | 2020-05-23 | 2021-12-02 | Pakravan Nafiseh | Sperm head for resolution of inflammation, tissue repair & regeneration, and restoration of tissue function: new approach of cell therapy |
CN114231481B (en) * | 2021-12-21 | 2023-07-18 | 中国人民解放军总医院 | Chemical induction method for taking reprogramming Cheng Zhenpi fibroblast as endothelial progenitor cell |
WO2023217126A1 (en) * | 2022-05-10 | 2023-11-16 | 上海赛立维生物科技有限公司 | Renal epithelial precursor-like cell, and preparation method therefor, preparation thereof and use thereof |
WO2024050517A1 (en) * | 2022-09-02 | 2024-03-07 | The University Of North Carolina At Chapel Hill | Methods of making and using anticancer reprogrammed b cells |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554512A (en) * | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
US7112440B2 (en) * | 1995-02-02 | 2006-09-26 | Ghazi Jaswinder Dhoot | Method of increasing the relative number of CD45 low cells in a cell population |
US9068164B1 (en) * | 1995-02-02 | 2015-06-30 | Tristem Trading (Cyprus) Limited | Method of preparing an undifferentiated cell |
GB9502022D0 (en) * | 1995-02-02 | 1995-03-22 | Abuljadayel Ilham M S | A method for preparing lymphohaematopoietic progenitor cells |
WO1996035224A1 (en) * | 1995-05-02 | 1996-11-07 | Philips Electronics N.V. | Colour cathode ray tube |
US20050037490A1 (en) * | 1999-10-29 | 2005-02-17 | Lawrence Rosenberg | Medium for preparing dedifferentiated cells |
TWI288779B (en) * | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
WO2006014642A1 (en) * | 2004-07-22 | 2006-02-09 | Five Prime Therapeutics, Inc. | Method of producing autologous embryonic stem cells |
KR20110134939A (en) * | 2009-04-03 | 2011-12-15 | 더 맥클린 하스피털 코퍼레이션 | Induced pluripotent stem cells |
-
2009
- 2009-10-19 CN CN2009801630439A patent/CN102647989A/en active Pending
- 2009-10-19 AU AU2009354350A patent/AU2009354350B2/en not_active Ceased
- 2009-10-19 UA UAA201205968A patent/UA109265C2/en unknown
- 2009-10-19 EP EP09736651A patent/EP2490702A1/en not_active Withdrawn
- 2009-10-19 MX MX2012004522A patent/MX2012004522A/en unknown
- 2009-10-19 RU RU2012120713A patent/RU2635317C2/en not_active IP Right Cessation
- 2009-10-19 JP JP2012534757A patent/JP6073135B2/en not_active Expired - Fee Related
- 2009-10-19 CA CA2781522A patent/CA2781522A1/en not_active Abandoned
- 2009-10-19 KR KR1020127012911A patent/KR101766203B1/en active IP Right Grant
- 2009-10-19 WO PCT/GB2009/051396 patent/WO2011048350A1/en active Application Filing
- 2009-10-19 CH CH00524/12A patent/CH704227B1/en not_active IP Right Cessation
-
2012
- 2012-03-28 IL IL218902A patent/IL218902A/en not_active IP Right Cessation
- 2012-04-04 TN TNP2012000157A patent/TN2012000157A1/en unknown
- 2012-04-12 ZA ZA2012/02664A patent/ZA201202664B/en unknown
- 2012-04-19 CU CU2012000063A patent/CU24006B1/en active IP Right Grant
- 2012-05-11 MA MA34857A patent/MA33740B1/en unknown
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO2011048350A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP6073135B2 (en) | 2017-02-01 |
IL218902A0 (en) | 2012-06-28 |
RU2635317C2 (en) | 2017-11-10 |
KR101766203B1 (en) | 2017-08-08 |
TN2012000157A1 (en) | 2013-12-12 |
AU2009354350B2 (en) | 2015-09-03 |
RU2012120713A (en) | 2013-11-27 |
AU2009354350A1 (en) | 2012-04-19 |
CH704227B1 (en) | 2015-05-15 |
KR20120099686A (en) | 2012-09-11 |
CN102647989A (en) | 2012-08-22 |
UA109265C2 (en) | 2015-08-10 |
WO2011048350A1 (en) | 2011-04-28 |
CA2781522A1 (en) | 2011-04-28 |
CU20120063A7 (en) | 2012-10-15 |
JP2013508343A (en) | 2013-03-07 |
IL218902A (en) | 2017-06-29 |
MX2012004522A (en) | 2012-05-08 |
CU24006B1 (en) | 2014-06-27 |
MA33740B1 (en) | 2012-11-01 |
ZA201202664B (en) | 2013-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009354350B2 (en) | Treatment using reprogrammed mature adult cells | |
US20140234268A1 (en) | Treatment using reprogrammed mature adult cells | |
JP5636415B2 (en) | Modulation, assay and use of stem and progenitor cell differentiation | |
US8828375B2 (en) | Expansion of haemopoietic precursors | |
CN108478599A (en) | Mesenchyma stromal cells and its associated uses | |
JP2002502617A (en) | Methods for controlling proliferation and differentiation of stem and progenitor cells | |
JP2009536163A (en) | Immunological tolerance and regulatory progenitor cells | |
US20170106021A1 (en) | Compositions enriched for hox11+ stem cells and methods of preparing the same | |
CN107641617B (en) | System for efficiently preparing megakaryocytes and platelets of non-human primates in vitro and application of system | |
US20080206196A1 (en) | Differentiation of cord blood into neural like cells, and method to treat neurological condition patients | |
GB2474492A (en) | Treatment of medical conditions using reprogrammed cells | |
JP2017008049A (en) | Treatment using reprogrammed mature adult cells | |
CN114901806A (en) | Cell population and method for obtaining same | |
TW201114895A (en) | Treatment using reprogrammed mature adult cells | |
AU2017216530A1 (en) | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120503 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1175111 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20140804 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20181027 |